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ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) is characterized by
immunosuppression, a state in which the established tumor evades the immune response.
This presents a significant obstacle for treatment and the five-year survival rate for head
and neck cancer patients remains at approximately 50%. While HNSCC causes profound
immune inhibition, the immune changes that occur before HNSCC becomes established,
at the premalignant lesion stage, are unknown. This study used the 4-nitroquinoline
1-oxide (4-NQO) mouse model of oral carcinogenesis to investigate how the immune
environment changes as premalignant lesions progress to tumor. Premalignant lesionbearing tongue tissue was found to release increased levels of Th1- and Th17-associated
cytokines, including IL-2, IFN-γ, TNF-α and IL-17A, compared to control and
HNSCC-bearing tongue tissue. Spleen cells and cervical lymph node cells produced
increased levels of Th1- and Th2-associated cytokines in the presence of premalignant
lesion-bearing tongue tissue compared to HNSCC-bearing tongue tissue. Premalignant
lesion cells secreted significantly increased levels of proinflammatory G-CSF, RANTES,
MCP-1, and PGE2 compared to HNSCC cells. Premalignant lesion cell supernatant
elicited increased production of innate proinflammatory mediators and Th1- and
Th17-associated cytokines from spleen cells compared to HNSCC cell supernatant or
media alone. An increased percentage of spleen cells expressed markers of activation in
the presence of premalignant lesion cell supernatant compared to HNSCC cell
supernatant or media alone. This data shows that premalignant lesion cells release
increased levels of proinflammatory mediators compared to HNSCC cells, and
x
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furthermore, elicit increased production of Th1- and Th17-associated cytokines and
expression of activation markers in spleen cells compared to HNSCC cells. Compared to
the HNSCC environment, the premalignant lesion environment is significantly more
immune stimulatory, supporting a robust Th1- and Th17-associated immune response.
Immunosuppression is a significant obstacle to treatment for advanced HNSCC
patients. The tumor itself plays a role in establishing this local and systemic
immunosuppression, by secreting mediators such as PGE2 that decrease T cell-mediated
immunity and support immunosuppressive cells at the tumor site. This study aims to
determine if inhibition of PGE2 production at an earlier stage of carcinogenesis, the
premalignant lesion stage, can restore a beneficial immune response and slow progression
to tumor, in the 4-NQO mouse model of oral carcinogenesis. Initial studies showed that
inhibition of PGE2 production by premalignant lesion cells (but not HNSCC cells)
induced increased production of the Th1-associated cytokine IL-2 and IFN-γ by spleen
cells in vitro. To monitor the effects of inhibiting PGE 2 production in vivo, indomethacin,
a COX (cyclooxygenase) inhibitor, was administered to mice bearing 4-NQO-induced
premalignant lesions and progression to tumor was monitored by endoscopy. Mice
receiving indomethacin at the premalignant lesion stage had significantly improved
clinical outcomes compared to mice receiving diluent control treatment, as defined by
lower lesion scores. Cervical lymph node analysis showed an increased percentage of
CD8+ T cells expressing IFN-γ at the endpoint of the study (20 weeks) in mice that had
received indomethacin compared to mice that had received diluent control treatment,
although the difference was not significant. Spleen cells from mice that had received
xi
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indomethacin secreted increased levels of IFN-γ at 6 weeks and 20 post-treatment
compared to mice that had received control treatment, suggesting that indomethacin
treatment induced an increased systemic Th1-type immune response. The data suggests
that the premalignant state is characterized by an immune stimulatory and inflammatory
milieu and that inhibiting PGE2 production stimulates immune reactivity and slows
progression to advanced HNSCC in the 4-NQO model.
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CHAPTER 1: IMMUNE REACTIVITY AND HNSCC
1.1 An Introduction to Head and Neck Squamous Cell Carcinoma (HNSCC)
1.1.1 Development of HNSCC
Head and neck squamous cell carcinoma (HNSCC) accounts for over 90% of all
head and neck cancers, with approximately 550,000 cases diagnosed each year
worldwide [1, 2]. The major risk factors are tobacco and alcohol abuse, which have a
synergistic effect on disease progression. HNSCC arises from keratinizing epithelial cells
in the mucosa throughout the head and neck region, including the lip, oral cavity, nasal
cavities, paranasal sinuses, pharynx and larynx. The development of HNSCC begins with
the formation of leukoplakias or erythroplakias which, if left untreated, progress to
carcinoma in situ and, finally, invasive carcinoma [3]. Because of the aggressive nature
of the disease, the five-year survival rate for head and neck cancer patients remains
around 50%, despite some advances in treatment over that last 30 years. A significant
complication for treatment is that patients typically present with advanced tumors, which
drastically reduces the effectiveness of traditional treatment strategies, including surgical
resection and a combination of chemotherapy and radiation. In addition to having limited
success, current treatment options greatly diminish patient quality of life, contributing to
salivary gland hypofunction, xerostomia, bacterial infections, inflammation of the
mucous membranes, and in some cases, malnutrition and dehydration due to the patient’s
inability to eat and drink [4]. A majority of patients presenting with advanced tumors
relapse locoregionally and/or at distant sites after initial treatment, at which point
treatment by surgery, if possible, and reirradiation are significantly less successful [5-7].
Chapter 1
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1.1.2 Complications to Current Treatment Options
Advanced HNSCC tumors use a variety of mechanisms to evade the host immune
response and promote immunosuppression, presenting perhaps the most important
obstacle for effective treatment and contributing to the high recurrence rate of this
disease. HNSCC patients are characterized by systemic immunosuppression, exhibiting
increased populations of regulatory T cells and CD34+ progenitor cells, which suppress
CD8+ T cell- and CD4+ helper T cell-mediated immunity at the primary tumor site and
are associated with a poorer prognosis [8-11]. Increased levels of CD127lo/- regulatory T
cells in HNSCC patients are associated with more advanced malignancies involving local
lymph nodes [12]. Similarly, increased levels of CD34+ progenitor cells are associated
with increased tumor recurrence and metastasis [10]. While some immunotherapies,
including IL-2/Interferon-gamma (IFN-γ) cytokine therapies and cetuximab/
nimotuzumab anti-epidermal growth factor receptor (EGFR) therapies have been shown
to increase lymphocyte infiltration, prevent tumor progression and increase long-term
survival when used in combination with standard treatment, responses vary greatly
among patients and are often associated with significant toxicity [13-17]. Furthermore,
some discrepancies in immune vs. clinical responses have been observed in trials with the
anti-EGFR antibody nimotuzumab, in which clinical responses were not associated with
significant lymphocyte activation [15]. A gap remains in our understanding of how
HNSCC patients respond to immunotherapies since the immune changes that take place
during the progression of HNSCC and how the tumor evades an effective immune
response have not been completely mapped out.
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1.2 Evasion of Immune Response by HNSCC Tumors
1.2.1 Immune Escape in HNSCC
It is well established that HNSCC tumors are associated with immune escape. The
process of immunoediting is harnessed by many different types of tumors and generally
begins with elimination, in which patrolling T helper cells recognize an invasive growth
and send inflammatory signals to recruit natural killer (NK), NK T cells, macrophages,
and dendritic cells to the site of the dysplastic tissue to mount an initial response [18].
During this stage, NK cells and antigen-presenting cells are transactivated by IFN-γ and
IL-12 secretion and tumor cells are eliminated by TNF-related apoptosis-inducing ligand
(TRAIL), perforin, and reactive nitrogen species. Tumor-specific CD4+ and CD8+ T cells
begin to hone to the developing tumor as well, initiating the adaptive antitumor response
[18]. The second stage of immunoediting is characterized by a dynamic equilibrium
between the developing tumor bed and the host’s immune system, and may last up to
several years. During this stage, IFN-γ- producing CD4+ and CD8+ T cells are unable to
completely eliminate the rapidly dividing/mutating HNSCC tumor cells. During the final
stage of immunoediting, tumor escape, HNSCC tumor cells decrease antigen, major
histocompatibility complex (MHC) I/II and costimulatory molecule expression to directly
thwart an effective immune response [19-23]. In addition, by upregulating death ligands
such as FasL and PD-L1, HNSCC tumors trigger apoptosis in infiltrating lymphocytes,
further dampening the immune response at the tumor site [24, 25]. Infiltrating
immunosuppressive populations, including myeloid-derived suppressor cells (MDSCs)
and T regulatory cells, contribute to tumor-associated immunosuppression by directly
inhibiting CD8+ T cell-mediated immunity and promoting tumor growth [1, 12, 26].
Chapter 1
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1.2.2 Immune Environment of HNSCC
A significant complication of understanding how the tumor contributes to
immunosuppression is the complex network of tumor cells, fibroblasts,
carcinoma-associated fibroblasts (CAFs), smooth muscle cells, endothelial cells, and
myriad of tumor-infiltrating immune populations including tumor-associated
macrophages, B cells, T cells and antigen-presenting cells that make up the tumor
microenvironment [27]. One of the major mechanisms by which HNSCC tumors are
thought to evade host immune recognition is by modulating the cytokine environment at
the tumor site. By secreting cytokines such as IL-6 and IL-10, HNSCC tumor cells
promote a T helper cell type 2 (Th2)-skewed response, which is associated with
decreased antitumor efficacy [20, 28]. This Th2-skewing is also evident systemically, as
peripheral blood mononuclear cells (PBMCs) isolated from advanced HNSCC patients
secrete abnormally high levels of Th2 cytokines [29, 30]. Along with Th2-skewed
cytokines, HNSCC tumors secrete increased levels of immunosuppressive factors such as
transforming growth factor-beta (TGF-β) that function to directly inhibit cytotoxic T
cell-mediated immunity and recruit immunosuppressive cells, including MDSCs and
M2-skewed macrophages, to the tumor site [31, 32]. Once at the tumor site, HNSCC
tumor cells harness these immunosuppressive cells for a myriad of tumor-promoting
functions, including increased growth and angiogenesis. HNSCC cells trigger increased
IL-6 production from CD34+ progenitor cells, for example, promoting angiogenesis in the
tumor microenvironment [33].
HNSCC tumors also secrete factors that are typically associated with a
proinflammatory response, harnessing these immune modulators to favor growth,
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angiogenesis and paradoxically, immune escape. Several of these mediators have also
been shown to recruit immunosuppressive cells to the tumor site. Granulocytemacrophage colony-stimulating factor (GM-CSF) and prostaglandin E2 (PGE2), which
have traditional proinflammatory roles that support the differentiation of macrophages
and neutrophils in the early stages of inflammation, are significantly increased in the
supernatant of primary SCC lines from patients with head and neck cancer [34].
Tumor-secreted GM-CSF has been shown to promote MDSC recruitment and
differentiation, and high levels of GM-CSF in HNSCC patients are associated with a
poorer prognosis [10, 35]. Increased levels of PGE2 are associated with invasion and
angiogenesis in aggressive early-stage tumors [36]. Other factors secreted by HNSCC
tumors, including monocyte chemotactic protein-1 (MCP-1), have been shown to
contribute to immunosuppression at the tumor site by recruiting a population of IL-10
and TGF-β-secreting M2 skewed tumor-associated macrophages [37]. By secreting a host
of immune modulators, HNSCC tumors thwart an effective immune response and
become increasingly difficult to treat.
1.3 Role of Prostaglandin E2 in HNSCC
1.3.1 Role of PGE2 in Cancer
The role of PGE2 in tumor progression has not been clearly defined. One reason
for this is that PGE2 is produced by a myriad of cell types, including epithelial cells,
fibroblasts, infiltrating immune cells and cancer cells, all of which comprise/surround a
developing tumor [38]. Furthermore, the role of PGE2 seems to shift during tumor
progression. During early stages of inflammation, PGE2 has been shown to promote the
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infiltration of neutrophils, macrophages and mast cells [39-41]. However, PGE2 has been
shown to have an inhibitory effect on granulocyte function and macrophage
phagocytosis, contributing to defective innate immunity in cancer patients and patients
who have undergone bone marrow transplantation [38, 42-45]. PGE2 also inhibits several
arms of adaptive immunity. It has been shown to directly inhibit IL-2 production by T
cells, decrease IL-2 responsiveness and suppress antigen-specific T cells [46, 47]. Several
studies have shown that PGE2 disrupts normal dendritic cell differentiation and
suppresses the activity of T helper cell type 1 (Th1)-associated dendritic cells (DCs),
resulting in decreased IL-12 production and Th2 skewing of mature T helper cells [4851]. These PGE2-skewed DCs, or MDSCs, have been shown to the suppress cytotoxic T
cell responses, skew macrophage differentiation towards the pro-tumor M2 phenotype
and contribute to overall dendritic cell dysfunction in the cancer setting [52-55].
However, the effect of PGE2 on mature dendritic cells is more immune stimulatory. PGE 2
promotes the surface expression of chemokine receptor 7 (CCR7) and costimulatory
molecules, contributing to DC migration to lymph nodes and their subsequent activation
[49, 56-59]. All in all, the role of PGE2 on immune function is complex and there remains
a gap in our knowledge of how PGE2 contributes to tumor progression.
1.3.2 PGE2 and COX Inhibitors in HNSCC
It is well established that arachadonic acid metabolism is altered in established
HNSCC tumors. COX-2, the inducible enzyme involved in PGE2 production, is
significantly upregulated in HNSCC tumors and increased levels of PGE 2 are associated
with decreased levels of CD8+ T cells and increased levels of suppressor cells at the
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tumor site [20, 26, 28, 60]. Preliminary studies have shown that inhibiting COX-2 leads
to increased apoptosis and decreased angiogenesis of HNSCC cells, both in vitro and in
vivo [61]. In several murine and hamster models of head and neck cancer, administration
of the COX-2 inhibitor celecoxib to animals with tumors resulted in decreased tumor
expression of vascular endothelial growth factor (VEGF) and survivin, increased tumor
cell apoptosis, and decreased tumor growth [61-63]. However, the impact of
administering a COX inhibitor before tumors become established, at the premalignant
lesion stage, has not been previously investigated.
COX-2 inhibitors are being explored as a possible adjuvant to traditional therapies
in head and neck cancer treatment. In one study of head and neck cancer patients,
preoperative administration of the COX-2 inhibitor Rofecoxib resulted in restored
monocyte function and migration, suggesting that inhibiting COX-2 may be a key
strategy in restoring immune function [64]. One retrospective study looking at the
relationship between the use of nonselective cyclooxygenase inhibitors and overall
survival in HNSCC patients found that median survival was increased among COX
inhibitor users, although the regimen/type of COX inhibition was not controlled for in
this study [65]. In several clinical trials, administration of celecoxib as an adjuvant
therapy for head and neck cancer patients has been associated with significant response
rates [66-68]. However, the mechanism by which COX-2 inhibition may be altering the
immune response in HNSCC patients has not been extensively explored.
Some of the mechanisms by which PGE2 may be modulating the immune
response in other types of malignancies, including colorectal, lung, and breast cancers,
Chapter 1

8

Introduction: Immune Reactivity
and HNSCC

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
are starting to be defined. Several studies have shown that PGE2 induces the production
of IL-10 and directly suppresses the production of proinflammatory cytokines by CD4+ T
cells, implicating it as a key player in tumor-associated immunosuppression [26, 38, 69,
70]. In a model of lung carcinoma, inhibition of COX-2 resulted in increased antitumor
reactivity by shifting the cytokine balance of resident immune cells towards a more
proinflammatory, Th1-like phenotype, as characterized by increased IL-12 production
and decreased IL-10 production [71]. The role of PGE2 in modulating the immune
response in head and neck cancer—and specifically what role PGE2 plays as
premalignant lesions progress to HNSCC tumors—has not been previously investigated
and is the focus of Specific Aim 2 of this dissertation.
1.4 Premalignant Lesions
1.4.1 Immune Environment of Premalignant Lesions
A critical gap that remains in head and neck cancer research is the progression of
premalignant lesions to established HNSCC. There has been little focus on the
premalignant state of HNSCC, and the molecular and immunological conditions that
foster development into established HNSCC. A major challenge is that patients typically
present with more advanced tumors, so studies on the premalignant lesion state are less
complete. In one study, premalignant lesion tissue extracted from patients secreted
increased levels of Th1-associated IL-2 and IFN-γ and T helper cell type 17
(Th17)-associated IL-17A compared to HNSCC tissue and normal oral tissue [72].
Premalignant lesion tissue also released increased levels of pro-inflammatory IL-6
compared to HNSCC tissue and healthy oral tissue [72]. This study shows that
Chapter 1
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premalignant lesion tissue is more proinflammatory than HNSCC tissue and suggests that
it may be more immune stimulatory compared to the established tumor. The immune
changes observed at the site of the premalignant lesion or HNSCC tumor do not
necessarily reflect changes in the immune response systemically. In the same study,
levels of IL-2 and IFN-γ were not increased in the plasma of patients bearing
premalignant lesions compared to HNSCC and control patients [72]. IL-17A, however,
was increased in the plasma of patients bearing premalignant lesions compared to
HNSCC and control patients, reflecting what was observed in premalignant lesion tissue
[72]. Several studies have shown that IL-6 and tumor necrosis factor-alpha (TNF-α) were
increased in the saliva of patients with premalignant oral lesions compared to control
patients [73, 74], suggesting that a local inflammatory response occurs in the oral cavities
of patients with developing lesions. Premalignant oral lesion epithelium has been shown
to expresses several proinflammatory molecules, including TNF-α, stromal cell-derived
factor 1 (SDF-1 or CXCL12), and the toll like receptors TLR4 and TLR9, which promote
an inflammatory immune response [75-77].
Another difficulty in understanding the premalignant lesion environment is the
complex network of epithelial cells, fibroblasts, endothelial cells, muscle cells, and
infiltrating immune cells that make up the developing lesions. The contribution of
inflammatory immune cells vs. resident cells such as endothelial cells and fibroblasts to
the proinflammatory milieu of premalignant lesions is not always straightforward.
Several studies have shown that premalignant lesions are characterized by an influx of
proinflammatory immune cells, including NK cells, macrophages, and CD8+ T cells [78,
79]. In these studies, the infiltration of NK cells and CD8+ T cells into premalignant
Chapter 1
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lesions correlated with the degree of dysplasia [78, 79]. Dendritic Langerhans cells were
also found to be increased in leukoplakias with dysplasia and were co-localized with T
cells in many cases [78, 79]. There is evidence that CD8+ T cells are more activated in
premalignant lesions, as they have been shown to express increased levels of granzyme B
and perforin in premalignant lesion tissue vs. in control tissue [80]. Endothelial cells also
play a role in modulating the immune environment of premalignant lesions through their
production of VEGF, PGE2, IL-6, and TGF-β [81-83]. These factors recruit immune cells
into premalignant lesions and also modulate their activity once at the site of the
developing lesions. Because lesions are composed of such a complex network of cells
and patients rarely present with such an early stage of disease, there remains a critical gap
in our knowledge of the immune environment of premalignant lesions, and how
premalignant lesion cells themselves, may be modulating the immune response.
1.4.2 4-NQO Mouse Model of Oral Carcinogenesis
The 4-NQO mouse model produces all stages of oral carcinogenesis and allows
careful observation of the immune environment as premalignant lesions progress to
HNSCC. This model is based on the carcinogenic effects of 4-NQO, which can be
administered in the drinking water of C57BL/6 mice and mimics the effects of tobacco, a
major risk factor for HNSCC [84, 85]. Other models of HNSCC, including the xenograft
model in which human HNSCC cells are injected subcutaneously or into the mylohyoid
muscle of the mouse oral cavity, do not allow for the study of multistep carcinogenesis or
the contribution of the immune system on the progression of HNSCC from the
premalignant state to established tumor. In addition, because injected tumor cells do not
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originate from the epithelium of the head and neck region, the molecular changes that
occur as normal epithelium becomes dysplastic cannot be tracked [86-88]. The
7,12-dimethylbenz[a]anthracene (DMBA) Syrian hamster cheek model induces
premalignant oral lesions with genetic/epigenetic alterations that mimic human HNSCC,
but because humans do not have an anatomic pouch, these tumors do not resemble human
tumors anatomically or histologically [89-91].
The 4-NQO model of oral carcinogenesis induces the formation of premalignant
oral lesions that progress to exophytic, HNSCC tumors. At the molecular level, 4-NQO
causes the formation of reactive oxygen species (ROS), DNA adducts (adenosine to
guanosine substitutions) and H-ras mutations, mimicking the DNA damage induced by
tobacco and alcohol use, and therefore modeling human disease at the molecular level
[92-94]. One of the strengths of the 4-NQO model is that 4-NQO is a water-soluble
quinoline derivative that can be administered in the drinking water, so the mice are
constantly exposed to the carcinogen, as a model human disease [95, 96]. The most
relevant strength of the 4-NQO model is that it allows the immune response to be studied
as premalignant lesions progress to HNSCC tumors. Administration of 4-NQO in the
drinking water at a concentration of 50 μg/mL results in the formation of premalignant
lesions on the tongue at 6-8 weeks, which progress to more exophytic, malignant tumors
by 12-16 weeks. Because tumors formed in this model of oral carcinogenesis closely
mimic HNSCC tumors in human patients at both the histological and molecular levels,
the 4-NQO model is an ideal candidate for immunotherapy studies [95, 97-99].

Chapter 1

12

Introduction: Immune Reactivity
and HNSCC

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
1.4.3 Changes in the Immune Response as Premalignant Lesions Progress to
HNSCC
Initial studies using the 4-NQO mouse model of oral carcinogenesis offer some
insight into the immune changes that take place during the development of HNSCC. To
investigate the immune response against developing oral tumors, these studies focused on
immune cell infiltration into the tumor-draining, cervical lymph nodes of mice with
4-NQO-induced oral lesions and 4-NQO-induced established tumors. These studies
showed that tumor-draining lymph nodes of HNSCC-bearing mice are characterized by
an increase in the percentage and absolute number of CD4+Foxp3+ regulatory T cells
compared to lymph nodes of premalignant lesion-bearing and control mice,
demonstrating that there is increased infiltration of immunosuppressive cells in the
established tumor state [100]. This mirrors the increase in T regulatory cells observed
both in the periphery and in the tumors of HNSCC patients, supporting the 4-NQO model
as a closely representative model of human disease [8-12]. In contrast, cervical lymph
nodes of premalignant lesion-bearing mice are characterized by an increased percentage
and absolute number of proinflammatory Th17 cells compared to lymph nodes of
HNSCC-bearing mice and control mice, suggesting that the premalignant lesion state is
proinflammatory but as the lesion progresses to tumor, the immune response wanes and
immunosuppressive cells dominate. While the absolute numbers of conventional CD4+
and CD8+ T cells are increased in the cervical lymph nodes of HNSCC-bearing mice
compared to that in premalignant lesion-bearing and control mice, conventional CD4+ T
cells isolated from the cervical lymph nodes of HNSCC-bearing mice were characterized
by decreased proliferation and secreted decreased levels of IL-2 upon stimulation in vitro
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compared to T cells isolated from control mice [100]. Taken together, these data showed
that conventional CD4+ T cells isolated from mice bearing established HNSCC tumors
are functionally compromised compared to T cells isolated from control mice and, to
some extent, premalignant lesion-bearing mice as well. These studies suggest that the
tumor environment may be more immune inhibitory compared to the premalignant lesion
environment. Future studies are necessary to determine how the immune response
evolves from the premalignant lesion to established HNSCC and how this impacts on
tumor progression.
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CHAPTER 2: RATIONALE, HYPOTHESIS, AND SPECIFIC AIMS
2.1 Rationale
It is well established that advanced HNSCC is associated with local and systemic
immunosuppression. Previous studies have shown that HNSCC tumors produce several
immune inhibitory factors, including TGF-β and PGE2, which recruit immunosuppressive
cells and directly inhibit T cell function at the tumor site [8, 10, 11, 19, 20, 28, 31, 32,
70]. However, much less is known about factors produced by premalignant lesions, and
how the immune environment shaped by premalignant lesions impacts on the immune
response as lesions progress to tumor. A few patient studies have suggested that
premalignant lesions are more proinflammatory, characterized by increased production of
IL-6 and IL-17A, compared to HNSCC tumors [72-74]. Preliminary studies using the
4-NQO mouse model of oral carcinogenesis have shown that immune cells infiltrating the
lymph nodes draining premalignant lesions are more activated and produce higher levels
of proinflammatory cytokines (IL-17A) compared to immune cells infiltrating the
cervical lymph nodes of HNSCC-bearing mice [100]. Taken together, these data suggest
that immune environment of the premalignant lesions may be more immune stimulatory
than in the tumor environment. But little is known about the immune mediators produced
by premalignant lesion cells themselves, and how these mediators impact on immune cell
function at this stage.
Traditional treatment options for HNSCC patients, including surgery and
chemotherapy/radiation, are not successful in the majority of cases and the 5 year
survival rate for this disease remains less than 50% [2]. A major obstacle to treatment is
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the immunosuppressed state of HNSCC patients. While immunotherapies have been
successful in some cases, overall these therapies are not widely effective and many are
associated with considerable toxicity. Our lab is interested in modulating the immune
response at the premalignant lesion stage as a means to stimulate the antitumor response.
One mediator that is known to promote immunosuppression in the HNSCC environment
is PGE2. HNSCC tumors directly secrete PGE2 and while the immune effects of PGE2 in
the tumor environment are not completely mapped out, increased levels of PGE2 have
been correlated with decreased T cell function, increased infiltration of MDSCs, and a
worse prognosis in patients [20, 26, 28, 60, 69, 70]. The role of PGE2 in the premalignant
environment remains unknown. Our preliminary studies have shown that premalignant
lesion cells produce PGE2 in significantly higher levels than HNSCC cells [101]. This
suggests that PGE2 may be modulating the immune response at a much earlier stage of
disease than has been previously appreciated and inhibition of PGE2 at this stage may
lead to a greater immunity against tumor. After defining the immune milieu of
premalignant lesions, our goal is to understand how PGE2 impacts on the immune
response in the premalignant lesion environment and then to inhibit PGE2 production at
the premalignant lesion stage to sustain a Th1-type response and slow progression to
tumor.
2.1.1 Hypothesis
Our hypothesis is that the premalignant lesion environment is highly proinflammatory,
which supports a robust immune response, but as the tumor becomes established, the
immune environment becomes less immune stimulatory, resulting in decreased
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Th1-mediated immune responses. We also hypothesize that PGE2 is a key player in
skewing the immune stimulatory environment of the premalignant lesion to the
immunosuppressive environment of the HNSCC tumor and COX inhibition at the
premalignant lesion stage will sustain Th1-mediated responses and slow progression to
tumor.
2.1.2 Specific Aims
This hypothesis will be tested through the following specific aims:
Aim 1: To investigate how the immune environment changes as premalignant
lesions progress to tumor and how the evolution of the immune environment
impacts on immune cell activation and function in the 4-NQO mouse model of oral
carcinogenesis.
HNSCC tumors are known to secrete factors such as TGF-β and PGE2 that
dampen the immune response at the site of the tumor, and contribute to the
immunosuppression of established HNSCC. Considerably less is known about the
environment of premalignant lesions. The focus of this aim is to define the premalignant
lesion environment in the 4-NQO model and to determine how factors produced by
premalignant lesion cells impact on immune cell cytokine production and activation.
Aim 2: To prevent the immune skewing and tumor progression in 4-NQO-treated
mice by inhibiting PGE2 production at the premalignant lesion stage.
In the tumor environment, PGE2 is known to inhibit an effective antitumor
response in a number of ways, including recruitment of immune inhibitory cells and
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inhibition of conventional T cell function. Inhibition of PGE 2 production has been shown
to promote a more active immune response and lead to increased survival in HNSCC
patients. Our preliminary studies show that premalignant lesion cells produce high levels
of PGE2. The focus of this aim is to understand how PGE 2 modulates the immune
response in the premalignant lesion environment and how inhibiting PGE 2 production at
this stage impacts on immune cell function and tumor progression.
2.2 Significance
Head and neck cancer is the sixth most common cancer worldwide, with an
overall survival rate that remains below 50%. Patients often present with advanced
tumors and systemic immunosuppression, making treatment very challenging. Many
studies have focused on factors secreted by HNSCC tumors and how they contribute to
immunosuppression, both at the tumor site and systemically. Factors such as TGF-β and
PGE2 lead to decreased T cell reactivity at the tumor site and also modulate the activity of
systemic immune cells, skewing them to a Th2 phenotype and inhibiting an effective
antitumor response. It is evident that mediators produced by tumor cells play a
considerable role in controlling immunity. Therefore, therapies that activate the immune
response in patients at high risk of developing HNSCC may prove to be more effective as
adjuvant treatments to surgery or photodynamic therapies, or even as primary treatments
to prevent progression of lesions to cancer.
What is not evident is how mediators produced by premalignant lesion cells
impact on the immune response. One reason for this is a lack of studies focusing on
patients with premalignant lesion disease and the other is a focus on animal models that
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have primarily advanced disease. Our lab is interested in the immune response at the
premalignant lesion stage, and how the response changes as premalignant lesions
progress to HNSCC. The 4-NQO mouse model of oral carcinogenesis is ideal because it
produces all stage of oral carcinogenesis and is based on the effects of 4-NQO, a
carcinogen that induces DNA damage and models the effects of tobacco at the molecular
and histological levels. Our primary focus is to isolate premalignant lesion cells and
evaluate how factors produced by these cells impacts on immune cell activation and
function, compared to HNSCC cells. This model allows us to directly compare the
premalignant lesion and HNSCC environments, and tease apart the contribution of each
cell type to immune reactivity. Preliminary studies have shown that premalignant lesion
cells themselves produces high levels of PGE2. Although PGE2 is known to contribute to
immunosuppression in established HNSCC, its role in the premalignant lesion
environment is not defined. The 4-NQO model allows us to administer the COX inhibitor
indomethacin at the premalignant lesion stage to better understand the role of PGE2 in
modulating the immune response at this stage and to track how COX inhibition impacts
on tumor progression. By understanding how the immune response changes as
premalignant lesions progress to tumor, we can better tailor immunotherapies to promote
an effective antitumor response.
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CHAPTER 3: EFFECT OF THE PREMALIGNANT LESION AND HNSCC
ENVIRONMENTS ON IMMUNE CELL REACTIVITY

Aim 1: To investigate how the immune environment changes as premalignant
lesions progress to tumor and how the evolution of the immune environment
impacts on immune cell activation and function in the 4-NQO mouse model of oral
carcinogenesis.

3.1 Introduction
HNSCC accounts for over 90% of all head and neck cancers and, despite some
advances in treatment over the last 30 years, the five-year survival rate remains around
50% [1, 2]. HNSCC patients are characterized by systemic immunosuppression,
exhibiting increased populations of regulatory T cells and CD34+ progenitor cells, which
suppress CD8+ T cell- and CD4+ helper T cell-mediated immunity at the primary tumor
site and are associated with a poorer prognosis [8-12]. By evading the immune response,
HNSCC tumors become increasingly difficult to treat and are also characterized by a high
recurrence rate.
Several of the ways in which HNSCC tumors evade the host immune response
have been defined. Over the course of immune escape, HNSCC cells lose MHC and
costimulatory molecule expression and secrete immune inhibitory factors such as TGF-β
and PGE2, inhibiting an effective cytotoxic T cell response and allowing the tumor to
persist [19-22, 26, 31, 32, 60]. HNSCC tumors also secrete factors that are typically
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associated with a proinflammatory response, harnessing these immune modulators to
favor growth, angiogenesis and, paradoxically, immune escape. GM-CSF and MCP-1,
which have traditional proinflammatory roles that support the differentiation of
macrophages and neutrophils in the early stages of inflammation, are significantly
increased in the supernatant of primary SCC lines from patients with head and neck
cancer and have been shown to promote MDSC recruitment and differentiation as well as
M2 macrophage polarization [10, 35, 37]. Secretion of these factors by HNSCC tumors
has been correlated with patient prognosis. High levels of GM-CSF in HNSCC patients
are associated with a poorer prognosis and increased levels of PGE2 are associated with
invasion and angiogenesis in aggressive early-stage tumors [10, 20, 36, 60]. These studies
indicate that factors secreted by HNSCC tumors play a direct role in modulating a
patient’s immune response, which plays a critical role in their prognosis and treatment
options.
There remains a critical gap in our understanding of the immune changes that
occur before HNSCC becomes established, at the premalignant lesion stage. One study
analyzing tissue from patients with premalignant oral lesions, showed that premalignant
lesion tissue releases increased levels of several proinflammatory cytokines, including
IL-2, IFN-γ, and IL-17A, compared to HNSCC tissue [72]. Preliminary studies using the
4-NQO mouse model of oral carcinogenesis have shown that the cervical lymph nodes of
premalignant lesion-bearing mice are characterized by an increased percentage of
activated T cells and increased levels of proinflammatory cytokines, including IL-17A
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[100]. These data suggest that an active immune response is taking place in the
preneoplastic stage and that this response is thwarted once the tumor becomes
established. However, the mediators released directly by premalignant lesion cells
themselves and how they impact on the immune response as the tumor becomes
established remains unknown.
The current study uses the 4-NQO mouse model to define the immune
environment of premalignant lesions at both the tissue and cellular levels, and to
determine how soluble mediators from cells established from carcinogen-induced oral
premalignant lesions and HNSCC tumors impact on immune cell activation and function.
Premalignant lesion-bearing tongue tissue was defined by increased Th1- and Th17associated cytokines compared to both HNSCC-bearing and control tongue tissue.
Premalignant lesion cells, themselves, secreted high levels of several proinflammatory
mediators, including G-CSF, RANTES, MCP-1, and PGE2. To determine how the
premalignant lesion and HNSCC environments modulate immune cell function and
activation, spleen cells from control C57BL/6 mice were cultured with media conditioned
by premalignant lesion cell-conditioned media or HNSCC cell-conditioned media.
Results of these studies showed that in the presence of premalignant lesion cellconditioned media, spleen cells produced significantly increased levels of Th1-, Th2- and
Th17-associated cytokines and an increased percentage of CD8+ T cells expressed the
activation marker CD69+, compared to spleen cells in the presence of HNSCC
cell-conditioned media or media alone. Premalignant lesion cell-conditioned media also
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elicited increased production of Th1-, Th2-, and Th17-associated cytokines from cervical
lymph node cells compared to HNSCC cell-conditioned media. Overall, these studies
showed that the premalignant lesion environment was more proinflammatory and elicited
a more activated immune response compared to the HNSCC environment.
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3.2 Materials and Methods
Oral HNSCC carcinogenesis
Five mg/mL 4-NQO in propylene glycol stock was diluted into the drinking water
at a final concentration of 50 μg/mL and administered to 2-month-old female C57BL/6
mice (Charles Rivers Laboratory, Wilmington, MA, USA) until the development of
premalignant oral lesions (6–8 weeks) or HNSCC (12–16 weeks). To monitor lesion
development, mice were examined endoscopically weekly using a Stryker 1.9 mm × 30°
endoscope and images were taken using a Stryker 1088 camera (Kalamazoo, MI, USA).
During the procedure, mice were sedated with inhaled isoflurane (Piramal Healthcare,
Boise, ID, USA).

Tongue processing and culture
After extraction, each tongue was minced and enzymatically digested using 100
μg/mL of complete liberase cocktail (Roche, Indianapolis, IN, USA) in 10 mL Hank’s
Buffered Saline Solution (HBSS, Life Technologies, Grand Island, NY, USA) at 37º C
for 4 h. Tissue was plated overnight in 12-well tissue culture plates (one dissociated
tongue/well) in Dulbecco’s Modified Eagle Media (DMEM) supplemented with 10%
FBS and penicillin/streptomycin/amphotericin B at 37° C. Tissue was restimulated with 2
μl/mL Cell Stimulation Cocktail (eBioscience) consisting of phorbol myristate acetate
(PMA) and ionomycin for the last 4-6 h of culture at 37º C and supernatant was collected
for cytokine/chemokine analysis. For each dissociated tongue, cytokine/chemokine levels
were standardized to total protein. To measure total protein, tissue was collected, washed
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with Dulbecco’s phosphate buffered saline (DPBS, Life Technologies, Grand Island, NY,
USA), resuspended in 1 mL phosphate buffered saline (PBS) and lysed using an
ultrasonic processor for 2 min. on ice. Total protein was quantitated using a BCA protein
assay kit (Thermo Scientific, Rockford, IL, USA).

Premalignant lesion and HNSCC cell lines
Primary cell lines were established by excising the tongues of premalignant or
HNSCC-bearing mice at the appropriate stage, as defined through histopathological analysis
by the oral pathology section in the Center for Oral Health Research at the Medical
University of South Carolina. Premalignant lesions or HNSCC were excised from the
tongues of 4-NQO treated mice. To establish cell lines, premalignant lesions or HNSCC
tumors were washed several times with PBS and antibiotic/antimycotic solutions containing
100 mg/mL penicillin, 100 mg/mL streptomycin, and 200 mg/mL neomycin. Premalignant
lesions or HNSCC tumors were plated on 60 mm tissue culture dishes in DMEM media
supplemented with 10% FBS and penicillin/streptomycin/amphotericin B and cultured for
two weeks at 37º C, replacing the media twice per week. After this period, adhering
premalignant lesion or carcinoma cells were removed and cultured in 75 cm2 flasks in fresh
media at 37° C, replacing the media twice per week. Prior to defining cells as
premalignant or HNSCC, their epithelial phenotype was confirmed as well as uniformity
of their microscopic and growth characteristics. To detach adherent cells, they were
trypsinized, washed, and resuspended in fresh medium. After cell lines were established,
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supernatants were collected after 48 h of culture (when cells reached 80% confluence) for
cytokine analysis.

Cytokine bead array
All reagents used for the cytokine bead array are from BD Biosciences unless
otherwise specified. The levels of IFN-γ, IL-2, IL-17A, IL-4, IL-6 and IL-10 in cell or tissue
cultures were determined using a mouse cytometric bead array (CBA) Th1/Th2/Th17
cytokine kit. Levels of IL-1α, IL-1β, IL-13, IL-12p70, IL-9, GM-CSF, G-CSF, MIG,
MCP-1, MIP-1α, MIP-1β and RANTES in cell or tissue cultures were determined using
cytometric bead array flex sets for the individual cytokines according to the manufacturer’s
instructions. A FACS Canto (BD Biosciences, San Jose, CA, USA) flow cytometer was
used to quantify cytokine profiles and relative amounts of each cytokine were analyzed
using FCAP Array Software (manufactured by Soft Flow Hungary Ltd. for BD
Biosciences, San Jose, CA, USA). In experiments where premalignant lesion or HNSCC
supernatants were added to spleen cell cultures, cytokine levels in total spleen cell
supernatants were adjusted for baseline levels in premalignant or HNSCC supernatants.

TGF-β1 ELISA
To quantify TGF-β1 in cell supernatants, a sandwich ELISA was performed
according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA).
Before analysis, latent TGF-β1 was activated to immunoreactive TGF-β1 by addition of
HCl solution, as described by the manufacturer. Premalignant lesion and HNSCC cell
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supernatants were diluted 1:5 in sample diluent for analysis. Optical density at 450 nm
was measured using a Spectra Max M2 plate reader. Concentration of TGF-β1 was
determined using SoftMax Pro 5.4.2 plate reader software. A standard concentration
curve was generated for each independent experiment. Samples were analyzed in
duplicate for each of three independent experiments.

Prostaglandin E2 ELISA
To quantify PGE2 in cell supernatants, a competitive ELISA was performed
according to the manufacturer’s instructions (Pierce Biotechnology, Rockford, IL, USA).
Cell supernatants were diluted 1:2 for analysis. Optical density at 405 nm was measured
using a Spectra Max M2 plate reader. Concentration of PGE 2 was determined using
SoftMax Pro 5.4.2 plate reader software. A standard concentration curve was generated
for each independent experiment. Samples were tested in duplicate for each of three
independent experiments.

Spleen processing
Spleens were harvested from control C57BL/6 mice and homogenized using a
glass homogenizer. Cells were passed through a 70 μm cell strainer (BD Falcon, San
Jose, CA, USA) and rinsed with HBSS. Red blood cells were lysed by adding ACK
Lysing Buffer (Lonza, Walkersville, MD, USA) for 3 min. Splenocytes were then washed
twice with HBSS. Cell number was determined by counting cells excluding trypan blue
using a hemocytometer.
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Cervical lymph node processing
Cervical lymph nodes were harvested from control C57BL/6 mice and
homogenized using a Stomacher 80 homogenizer (Seward) set on high for 90 sec. Cells
were then passed through a 70 μm cell strainer (BD Falcon, San Jose, CA, USA) and
rinsed with HBSS. Cell number was determined by counting cells excluding trypan blue
using a hemocytometer.

Culture medium
Cell culture media consisted of 1X DMEM (Life Technologies, Grand Island,
NY, USA) containing 4.5 g/L D-glucose and L-glutamine, supplemented with 10% fetal
bovine serum (FBS, Sigma, St. Louis, MO, USA) and 1X antibiotic antimycotic solution
(Sigma, St. Louis, MO, USA) containing penicillin, streptomycin and amphotericin B. To
establish cell lines from premalignant lesions and HNSCC tumors, culture media was
supplemented with 2X antibiotic antimycotic solution for the first 2 weeks of culture.

Spleen cell cultures
Spleen cells were cultured in 12-well anti-CD3-coated tissue culture plates at
1X106 cells/well in fresh media or media conditioned by premalignant lesions or HNSCC
with IL-2 (R&D Systems, Minneapolis, MN, USA) for 72 hr at 37º C. Premalignant lesion
cell and HNSCC cell supernatants were diluted 1:2 in fresh media for culture with spleen
cells. Premalignant lesion-bearing and HNSCC tongue tissue supernatants were diluted 1:10
in fresh media for culture with spleen cells. For spleen cell cytokine analysis, cells were
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restimulated with 2 μL/mL Cell Stimulation Cocktail (eBioscience, PMA/ionomycin) for the
last 4-6 h of culture at 37º C and supernatants were collected for analysis by CBA. For
analysis of surface marker expression by flow cytometry, cells were gently collected
from tissue culture plates with 25 cm cell scrapers (Sarstedt, Inc., Newton, NC, USA),
washed once with stain buffer, and transferred to polystyrene tubes at 1X10 6 cells/tube
for analysis by flow cytometry. For analysis of intracellular cytokine expression by flow
cytometry, cells were restimulated with 2 μL/mL Cell Stimulation Cocktail (eBioscience,
PMA/ionomycin) and 0.6 μL/mL GolgiStop (BDBiosciences) for the last 4-6 h of culture at
37º C. Cells were gently collected from tissue culture plates with 25 cm cell scrapers
(Sarstedt, Inc., Newton, NC, USA), washed once with stain buffer, and transferred to
polystyrene tubes at 1X106 cells/tube for analysis by flow cytometry.

Cervical lymph node cell cultures
Cervical lymph node cells were cultured in 12-well anti-CD3-coated tissue culture
plates at 1X106 cells/well in fresh media or media conditioned by premalignant lesions or
HNSCC, with IL-2 (R&D Systems, Minneapolis, MN, USA) for 72 hr at 37º C.
Premalignant lesion cell and HNSCC cell supernatants were diluted 1:2 in fresh media for
culture with lymph node cells. For cytokine analysis, cells were restimulated with 2 μL/mL
Cell Stimulation Cocktail (eBioscience, PMA/ionomycin) for the last 4-6 h of culture at 37º
C and supernatants were collected for analysis by CBA.
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Flow cytometric analysis of spleen cells: surface markers
All antibodies and reagents for this section are from BDBiosciences unless
otherwise stated. Spleen cells were gently collected from tissue culture plates with 25 cm
cell scrapers (Sarstedt, Inc., Newton, NC, USA), washed once with stain buffer, and
transferred to polystyrene tubes at 1X106 cells/tube for flow cytometric analysis. Cells
were resuspended in 300 μL FACS block buffer, containing 2% FBS in sterile 1X PBS,
at 4º C for 15 min and centrifuged at 1000 rpm for 5 min. Cells were then incubated in
10 μL Fc block, containing anti-CD16/32 antibody at a 1:100 dilution in sterile 1X PBS,
at 4º C for 10 min to block nonspecific antibody binding to the cell surface. Cells were
stained with the following antibodies: FITC CD4, PE/APC CD8a, PE CD69, APC CD25
(eBioscience) and APC PD-1 (eBioscience). A tube of cells stained with the appropriate
isotype controls was included. Cells were washed twice in 1 mL stain buffer (BD
Biosciences) and resuspended in 400 μL stain buffer for analysis of extent and frequency
of positive cells on a FACS Canto flow cytometer.

Flow cytometric analysis of spleen cells: cytokine expression
All antibodies and reagents for this section are from BDBiosciences unless
otherwise stated. For cytokine staining, spleen cells were restimulated with 2 μL/mL Cell
Stimulation Cocktail (eBioscience, PMA/ionomycin) and 0.6 μL/mL GolgiStop for the last
4-6 h of culture at 37º C. Cells were then gently collected from tissue culture plates with
25 cm cell scrapers (Sarstedt, Inc., Newton, NC, USA), washed once with stain buffer,
and transferred to polystyrene tubes at 1X106 cells/tube for flow cytometric analysis.
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Cells were resuspended in 300 μL FACS block buffer, containing 2% FBS in sterile 1X
PBS, at 4ºC for 15 min and centrifuged at 1000 rpm for 5 min. Cells were then incubated
in 10 μL Fc block, containing anti-CD16/32 antibody at a 1:100 dilution in sterile 1X
PBS, at 4º C for 10 min to block nonspecific antibody binding to the cell surface. Cells
were washed twice in stain buffer, resuspended in 1 mL cold Cytofix (BD Biosciences),
and incubated for 20 min at 4ºC. Cells were centrifuged, washed twice in 1 mL stain
buffer (BD Biosciences), resuspended in 1 mL Perm/Wash Buffer (BD Biosciences) and
incubated for 15 min at room temperature. Cells were then centrifuged, resuspended in
50 μL BD Perm/Wash Buffer and incubated for 30 min at room temperature with equal
concentrations of antibodies or appropriate isotype controls: FITC CD4, APC/PE CD8a,
PerCP-Cy5.5 IFN-γ, and PE-Cy7 IL-17A. Cells were washed twice in 1 mL BD
Perm/Wash Buffer and resuspended in 400 μL stain buffer for analysis of extent and
frequency of positive cells on a FACS Canto flow cytometer.
Statistical analyses
Data were reported using the mean as a measure of central tendency + standard
error of the mean. To compare one variable condition between groups, a one-way
ANOVA analysis was initially performed (GraphPad Prism version 6.03 for Windows,
GraphPad Software, La Jolla, CA, USA). If differences were identified by the ANOVA
analysis, a two-tailed Student’s t test was then performed to determine significance of
differences between each of two groups (ex.: control vs. premalignant, control vs.
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HNSCC, premalignant vs. HNSCC) using GraphPad Prism version 6.03. Significance
was reported in the 95% confidence interval.
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3.3 Results
Premalignant lesion-bearing tongues release increased levels of Th-1 and Th17associated cytokines and chemokines compared to HNSCC-bearing and control tongues
Previous studies have shown that immune cells infiltrating the draining lymph
nodes of premalignant lesion-bearing mice are more activated and release increased
levels of proinflammatory cytokines compared to HNSCC-bearing and control mice,
suggesting that the premalignant lesion environment supports a more activated, Th1-type
response [100]. However, the immune response at the site of the developing premalignant
lesion of the tongue has not been extensively studied. To define the immune environment
of premalignant lesions as they progress to HNSCC, tongues were extracted from mice
bearing premalignant lesions or HNSCC tumors and tissue was analyzed for levels of a
spectrum of proinflammatory cytokines and chemokines. These studies showed that
premalignant lesion-bearing tongue tissue releases increased levels of Th1- and Th17associated cytokines and other proinflammatory mediators compared to HNSCC-bearing
and control tongue tissue. As shown in Figure 3.1 below, supernatant collected from
premalignant lesion-bearing tongue tissue cultures contained significantly increased
levels of Th1-associated IL-2, IFN-γ, and TNF-α compared to HNSCC-bearing and
control tongue tissue. In addition, the levels of Th17-associated IL-17A were increased in
supernatants collected from premalignant lesion-bearing tongue tissue cultures compared
to supernatants from HNSCC-bearing or control tongue tissue cultures, but variability of
values among samples precluded statistical significance. Other proinflammatory
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mediators, including GM-CSF and G-CSF (granulocyte-colony stimulating factor), were
reduced in HNSCC-bearing tongue tissue supernatants compared to premalignant lesionbearing and control tongue tissue supernatants but, unlike the increased levels of other
cytokines shown in Figure 3.1, are not increased in supernatants of premalignant lesionbearing tongue tissue vs. supernatants of control tongue tissue. In addition to increased
Th1- and Th17-associated cytokines, premalignant lesion-bearing tongue tissue released
increased levels of Th2-asociated cytokines, including IL-4, IL-6 and IL-10 compared to
control tongue tissue, although these differences were not as significant as Th1-associated
cytokines (data not shown). The levels of immune inhibitory TGF-β were not
significantly different in supernatants collected from control tongue, premalignant lesionbearing tongue, and HNSCC tongue cultures (data not shown).
These data show that the immune environment of tongue tissue bearing
4-NQO-induced premalignant lesions is more proinflammatory than the immune
environment of tongue tissue bearing established HNSCC, characterized by increased
levels of Th1- and Th17-associated cytokines. This suggests that an active, Th1- and
Th17-associated immune response occurs at the premalignant lesion stage, but as the
lesion progresses to HNSCC, the response wanes significantly, possibly contributing to
the immunosuppression evident in established HNSCC.
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Fig. 3.1 Premalignant lesion-bearing tongues release increased levels of Th1- and
pro-inflammatory mediators compared to HNSCC-bearing and control tongues.
Tongues were excised from control, premalignant lesion (PM)-bearing, and
HNSCC-bearing mice and mechanically and enzymatically digested in liberase.
Tongue tissue was cultured for 24 h, restimulated with PMA/ionomycin for the last
4 h of culture, and supernatants were collected for cytokine analyses by cytokine
bead array (CBA). Data shown represent mean + standard error of the mean (SEM) of
three independent experiments, each performed in duplicate. *p<0.05 **p<0.01
***p<0.001 ****p<0.0001 (2-tailed Student’s t test).
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Spleen cells produce increased levels of Th1- and Th2-associated cytokines in the
presence of premalignant lesion-bearing tongue supernatant compared to spleen cells
exposed to HNSCC-bearing tongue supernatant
The premalignant and HNSCC environments are complex and are composed of
preneoplastic and neoplastic cells, as well as infiltrating immune cells. To investigate
how the environments shaped by premalignant lesions vs. HNSCC tumors impact on
immune cell reactivity, supernatants from tongue tissue cultures from control,
premalignant lesion-bearing and HNSCC-bearing mice were cultured with spleen cells
from control C57BL/6 mice. In the presence of premalignant lesion-bearing tongue tissue
supernatant, spleen cells produced increased levels of Th1-associated IL-2 compared to
spleen cells in the presence of HNSCC-bearing tongue tissue supernatant (Figure 3.2).
Upon re-stimulation with PMA/ionomycin, spleen cells produced comparable levels of
IL-2 in the presence of control, premalignant lesion-bearing, and HNSCC-bearing tongue
tissue supernatant, demonstrating that spleen cells are capable of producing IL-2 in all
conditions, but they produce increased levels of IL-2 in the premalignant lesion-bearing
tongue tissue environment without stimulation. This supports the hypothesis that the
premalignant lesion environment is inherently more immune stimulatory than both the
control and HNSCC environments. The level of IFN-γ produced by spleen cells in the
premalignant lesion-bearing tongue tissue environment was increased compared to spleen
cells in the control tongue tissue environment (p=0.053) and, to a lesser extent, spleen
cells in the HNSCC tongue tissue environment (p=0.078). Re-stimulation with
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PMA/ionomycin resulted in a slight increase of IFN-γ production by spleen cells in the
premalignant lesion tongue tissue environment and a significant increase of IFN-γ
production by spleen cells in the HNSCC tongue tissue environment. As with IL-2, these
data show that spleen cells were capable of producing IFN-γ in all conditions, but they
produce increased levels of IFN-γ in the premalignant lesion-bearing tongue tissue
environment, without re-stimulation. In other words, HNSCC tongue tissue supernatant
alone was not enough to induce maximal IFN-γ production, but spleen cells could be
restimulated to produce levels of IFN-γ comparable to premalignant lesion-bearing
tongue tissue conditions.
A similar trend was evident for the production of Th2-associated cytokines by
spleen cells in the presence of premalignant lesion-bearing tongue tissue supernatant,
although overall the levels of these cytokines were lower compared to Th1-associated
cytokines (Figure 3.2). Spleen cells produced an increased level of IL-4 in the presence of
premalignant lesion-bearing tongue tissue supernatant compared to HNSCC-bearing
tongue tissue supernatant. However, the level of IL-4 produced by spleen cells in the
presence of control tongue tissue supernatant was not significantly different that the level
produced by spleen cells in premalignant lesion-bearing tongue tissue supernatant. After
re-stimulation, the level of IL-4 produced by spleen cells in the presence of
HNSCC-bearing tongue tissue supernatant was comparable to the level produced by
spleen cells in the premalignant lesion tongue tissue environment, indicating that spleen
cells were capable of producing IL-4 in the HNSCC environment after PMA/ionomycin
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stimulation. Spleen cells produced increased levels of IL-10 in the presence of
premalignant lesion-bearing tongue tissue supernatant compared to spleen cells in the
presence of both HNSCC-bearing tongue tissue supernatant and control tongue tissue
supernatant. After re-stimulation with PMA/ionomycin, the level of IL-10 produced by
spleen cells in the premalignant lesion tongue tissue environment was increased
compared to the level of IL-10 produced by spleen cells in the control tongue tissue
environment and HNSCC tongue tissue environment, although the difference between the
premalignant lesion tongue tissue environment and HNSCC tongue tissue environment
was not significant.
The levels of the proinflammatory mediators IL-17A and TNF-α produced by
spleen cells were comparable in the premalignant lesion tongue tissue and HNSCC
tongue tissue environments. Upon restimulation with PMA/ionomycin, the level of IL17A produced by spleen cells in the presence of premalignant lesion-bearing tongue
tissue supernatant was decreased compared to spleen cells in the presence of HNSCC
tongue tissue supernatant and control tongue tissue supernatant. A similar trend was
evident for spleen cell production of TNF-α, although after re-stimulation with
PMA/ionomycin, the level of TNF-α produced by spleen cells in the premalignant lesionbearing tongue tissue environment was not significantly different than the level produced
by spleen cells in the HNSCC tongue tissue environment.
These data support the hypothesis that the immune environment of premalignant
lesion-bearing tongue tissue elicits increased production of Th1-associated cytokines, and
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to a lesser degree, Th2-associated cytokines, by spleen cells compared to the immune
environment of HNSCC-bearing tongue tissue. These data suggest that the premalignant
lesion environment may support a more robust immune response, compared to the
established tumor environment.
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Fig. 3.2 Spleen cells stimulated to produce increased levels of Th1- and Th2associated cytokines in the presence of premalignant lesion-bearing tongue tissue.
Spleen cells from control C57BL/6 mice were cultured with media conditioned by
tongue tissue from control, premalignant lesion (PM)-bearing, or HNSCC-bearing
mice at a 1:10 dilution in fresh media for 72 h. Spleen cells remained unstimulated
or were restimulated with PMA/ionomycin for the last 4 h of culture and
supernatants were collected for cytokine analysis by cytokine bead array (CBA).
Data shown represent mean + SEM of three independent experiments, each performed
in duplicate. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001 ~p=0.053 ^^p=0.078
(2-tailed Student’s t test).
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Premalignant lesion cells release increased levels of proinflammatory mediators
compared to HNSCC cells
While the above-described studies showed the premalignant lesion environment
to be proinflammatory and capable of stimulating immune cell cytokine production, the
present study aimed to determine the contribution of premalignant lesion cells vs. the
complex premalignant lesion milieu to the immune stimulatory environment. Previous
studies have shown that both murine and human SCC cell lines and freshly isolated
primary HNSCC tumors secrete increased levels of a panel of immune mediators,
including IL-1α, IL-6, GM-CSF, TGF-β and PGE2 [20, 31, 34, 60, 102-104]. There has
been little to no focus on immune mediators released by premalignant lesion cells, and
how this compares to HNSCC cells in the 4-NQO model. To investigate this question,
tongues were extracted from premalignant lesion-bearing and HNSCC-bearing mice to
establish primary cell lines so that the levels of immune mediators released by the cells
themselves could be analyzed. It was not feasible to include comparison to control tongue
cells because normal epithelial cells do not grow in culture without added growth factor,
which would alter the properties of the cells. Analysis of supernatants collected from the
cell cultures showed that premalignant lesion cells secrete significantly increased levels
of several proinflammatory mediators compared to HNSCC cells (Figure 3.3). The levels
of G-CSF, RANTES (regulated on activation and normal T cell expressed and secreted),
and MCP-1, while detectable in HNSCC cell supernatant, were detected in much higher
levels in premalignant lesion cell supernatant. Of note, premalignant lesion cells released
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significant levels of PGE2 compared to HNSCC cells. In contrast, HNSCC cell
supernatant was characterized by increased levels of immune inhibitory TGF-β compared
to premalignant lesion cells. These data show that the levels of immune mediators
secreted by premalignant lesion cells vs. HNSCC cells are quite different and suggest that
the immune environment changes as premalignant lesions progress to tumor. Further,
these data show that premalignant lesion cells secrete significantly higher levels of
several proinflammatory mediators compared to HNSCC cells in vitro, supporting the
contribution of premalignant lesion cells to the immune stimulatory environment of
tongue lesions.
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Fig. 3.3 Premalignant lesion cells release increased levels of pro-inflammatory
mediators compared to HNSCC cells in vitro. Cell lines were established from
4-NQO-induced premalignant lesions or HNSCC tumors and grown to confluency.
Supernatants were collected after 48 h for cytokine and chemokine analyses. Data shown
represent 3 independent experiments performed in duplicate. *p<0.05 **p<0.01
***p<0.001 ****p<0.0001 (2-tailed Student’s t test).
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Spleen cells produce increased levels of innate proinflammatory mediators in the
presence of premalignant lesion cell supernatant compared to spleen cells exposed to
HNSCC cell supernatant or media alone
The results in Figure 3.2 show the stimulatory effect of premalignant tongue
tissue on normal spleen cell cytokine production, but not known is the contribution of
premalignant lesion cells to this inflammatory immune stimulation. To investigate how
factors produced by premalignant lesion and HNSCC tumor cells modulate the
production of innate proinflammatory mediators by immune cells, splenocytes were
cultured with premalignant or HNSCC cell-conditioned media, and supernatants were
collected for cytokine and chemokine analyses. To simplify visualization of the effects of
premalignant lesion cells vs. HNSCC cells on spleen cell cytokine production, data were
normalized to cytokine levels secreted by spleen cells cultured in media alone (control
cultures) and presented as fold change/control values. As shown in Figure 3.4, the levels
of proinflammatory IL-1α and Th1-associated RANTES secreted by splenocytes in the
presence of premalignant lesion cell supernatant were significantly increased compared to
levels secreted by spleen cells that were incubated with HNSCC cell supernatant or
media alone, with and without stimulation with PMA/ionomycin. The level of IL-1α
secreted by splenocytes in the presence of premalignant lesion cell supernatant increased
from about 40-fold/control to almost 70-fold/control after stimulation, whereas the level
of RANTES secreted by splenocytes was about 12-fold/control with and without
stimulation, respectively, in vitro. There were no significant differences in the levels of
Chapter 3

46

Effect of the Premalignant Lesion and
HNSCC Environments on Immune
Cell Reactivity

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
macrophage inflammatory protein-1 alpha (MIP-1α) and macrophage inflammatory
protein-1 beta (MIP-1β) secreted by splenocytes in the presence of premalignant and
HNSCC supernatant, respectively, compared to control (data not shown).
In addition to stimulating increased production of IL-1α and RANTES,
premalignant lesion cell supernatant elicited increased production of granulocyte and
macrophage-associated monokine induced by gamma interferon (MIG), G-CSF and
GM-CSF from splenocytes compared to HNSCC supernatant or media alone, with and
without stimulation. The amount of MIG secreted by splenocytes in the presence of
premalignant cell supernatant was about 15-fold the level secreted by splenocytes in the
presence of HNSCC cell supernatant or media alone, with and without stimulation.
Similarly, the level of G-CSF secreted by splenocytes in the presence of premalignant
cell supernatant was over 275-fold the level secreted by splenocytes in the presence of
HNSCC cell supernatant or media alone. The level of GM-CSF secreted by splenocytes
in the presence of premalignant cell supernatant was 88-fold/control, increasing to about
140-fold/control after stimulation in vitro, whereas the level secreted by splenocytes in
the presence of HNSCC cell supernatant was 2-fold/control, increasing to only 3fold/control after stimulation.
These data show the contribution of premalignant lesion cells to inflammatory
and immune stimulatory environment of the premalignant lesion. While premalignant
cells stimulate a significant proinflammatory innate response, HNSCC cells are
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significantly less immune stimulatory. This may be a key mechanism by which the
HNSCC tumor escapes an effective immune response.

Chapter 3

48

Effect of the Premalignant Lesion and
HNSCC Environments on Immune
Cell Reactivity

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC

Fig. 3.4 Splenocytes cultured with premalignant cell-conditioned media release
increased levels of innate proinflammatory mediators compared to
splenocytes cultured with HNSCC cell-conditioned media or fresh media
alone. Splenocytes from control C57BL/6 mice were incubated with fresh
medium or media conditioned by premalignant lesion cells or HNSCC cells, with
or without PMA/ionomycin stimulation for the last 4 h of culture. Supernatants were
collected from spleen cell cultures for cytokine and chemokine analyses after 72 h.
Cytokine and chemokine levels were standardized to levels produced by spleen cells
in media alone and data is shown as fold change/control. Data represent 3
independent experiments, each performed in duplicate. *p<0.05 **p<0.01 ~p=0.051
^^p=0.064 (2-tailed Student’s t test).
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Spleen cells produce increased levels of Th1- and Th17-associated cytokines in the
presence of premalignant lesion supernatant compared to spleen cells exposed to
HNSCC supernatant or media alone
The above studies showed that premalignant lesion cells elicit increased
production of innate proinflammatory mediators from immune cells compares to HNSCC
cells. The present study was conducted to determine the impact of premalignant lesion
cells on stimulating the production of Th1-, Th2- and Th17-type cytokines by immune
cells. To investigate how immune mediators produced by premalignant lesion cells and
HNSCC cells alters T cell-associated cytokines, spleen cells were cultured with media
conditioned by premalignant lesion cells or HNSCC cells and stained intracellularly for
IFN-γ expression. As shown in Figure 3.5a,b below, an increased percentage of CD4+ T
cells expressed IFN-γ in the presence of premalignant lesion cell-conditioned media
compared to HNSCC cell-conditioned media or fresh media alone. More prominent was
the increased percentage of CD8+ T cells that expressed IFN-γ in response to
premalignant lesion cell-conditioned media compared to HNSCC cell-conditioned media
or fresh media alone.
In addition to analysis by flow cytometric staining, supernatants were collected
from spleen cell cultures to investigate how premalignant lesion cell or HNSCC cell
supernatants impact on the secretion of a panel of Th1-, Th2-, and Th17-associated
cytokines. As described above, to simplify visualization of the effects of premalignant
lesion cells vs. HNSCC cells on spleen cell cytokine production, data were normalized to
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cytokine levels secreted by spleen cells cultured in media alone (control cultures) and
presented as fold change/control values. As shown in Figure 3.5c, we found that the level
of IL-2 secreted by splenocytes cultured with premalignant supernatant was significantly
higher (20-fold/control) than splenocytes cultured with HNSCC supernatant
(3-fold/control), after stimulation in vitro. Similarly, the levels of Th1-associated IFN-γ
and TNF were significantly higher in the supernatant of splenocytes cultured with
premalignant lesion cell supernatant compared to HNSCC cell supernatant, with and
without stimulation. This data further supports the hypothesis that the premalignant
environment supports a Th1-type response, whereas the tumor microenvironment does
not.
Similarly, splenocytes cultured with premalignant lesion cell supernatant
secreted significantly higher levels of IL-17A (78-fold/control) than splenocytes
cultured with HNSCC supernatant (1.2-fold/control), even without re-stimulation.
After stimulation with PMA/ionomycin, the amount of IL-17A secreted by
splenocytes in the presence of premalignant supernatant increased to over 120fold/control, whereas the amount of IL-17A released in the presence of HNSCC
supernatant increased only slightly to 1.4-fold/control. This suggests that while the
premalignant environment elicits a significant Th17-type response, the HNSCC
environment does not.
A similar trend was discovered with Th2-associated cytokines, although overall,
the levels of Th2-associated cytokine were lower compared to Th1-associated cytokines.
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The levels of IL-4 and IL-6 secreted by splenocytes cultured with premalignant lesion
cell supernatant were significantly higher than splenocytes cultured with HNSCC cell
supernatant or media alone. Before stimulation, the levels of IL-4 and IL-6 secreted by
splenocytes in the presence of premalignant supernatant were increased approximately
2-fold/control and over 150-fold/control, respectively. After stimulation in vitro, these
levels rose to over 4-fold/control for IL-4 and decreased slightly to 130-fold/control for
IL-6. The level of IL-10 was increased in the supernatant of splenocytes co-cultured with
premalignant lesion cell supernatant (about 124-fold/control) compared to HNSCC cell
supernatant (5-fold/control), although the difference was not statistically significant
(p=0.094). After restimulation with PMA/ionomycin, the level of IL-10 produced by
spleen cells in the presence of premalignant lesion cell supernatant (165-fold/control) was
significantly increased compared to spleen cells in the presence of HNSCC cell
supernatant (4-fold/control). Overall, these data indicate that premalignant lesion
supernatant elicits a significant Th1-, Th2-, and Th17-associated response, whereas
HNSCC supernatant is significantly less immune stimulatory.
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Fig. 3.5 Premalignant lesion cell-conditioned media elicits increased expression
of IFN-γ in CD4+ and CD8+ T cells and increased secretion of Th1-, Th2-, and
Th17-associated cytokines from spleen cells compared to cytokines produced in
HNSCC cell-conditioned media or media alone. Representative results (a) and
graphical representation (b) of flow cytometric staining of spleen cells from control
C57BL/6 mice cultured with media alone, premalignant lesion cell-conditioned
media, or HNSCC cell-conditioned media for 72 h. Spleen cells were restimulated
with PMA/ionomycin for the last 4 h of culture. Data show staining of spleen cells
from 3 independent experiments, run in duplicate. For cytokine analyses (c),
supernatants were collected from spleen cell cultures after 72 h and analyzed by
CBA. Cytokine levels were standardized to levels produced by spleen cells in media
alone and data is shown as fold change/control. Data represent mean + SEM. *p<0.05
**p<0.01 ***p<0.001 ****p<0.0001 ~p=0.094 ^^p=0.061 (2-tailed Student’s t-test).
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Increased percentage of CD4+ T cells express IL-2 receptor CD25 and CD8+ T cells
express activation marker CD69 in the presence of premalignant lesion cell supernatant
compared to expression in the presence of HNSCC cell supernatant
The immune environment shaped by HNSCC has been shown to impact on
immune cell activation and function [10, 20, 100, 105, 106]. Previous studies, as well as
the current study, suggest that immune cells are more activated in the premalignant lesion
environment [72, 100, 101]. The direct impact of immune mediators released by
premalignant lesion cells on the activation status of immune cells, however, is not well
defined. While the above studies showed premalignant lesion cell stimulation of spleen
cell cytokine production, an alternate approach was used to further demonstrate T-cell
stimulation. To further analyze how immune mediators released by premalignant lesions
cells and HNSCC cells impact on immune cell function, the expression of IL-2 receptor
CD25 and activation marker CD69 on spleen cells in the presence of supernatant
collected from premalignant lesion cell and tumor cell cultures was analyzed. In the
presence of premalignant lesion cell supernatant, an increased percentage of CD4+ T cells
expressed CD25 compared to HNSCC cell supernatant or media alone. This increase in
CD25 expression could reflect an increase in the percentage of T regulatory cells induced
in the premalignant lesion environment or it could be an indicator of increased T cell
activation. A similar trend was observed for CD8+ T cells, in which a greater percentage
expressed CD25 in the presence of premalignant lesion cell supernatant compared to
what was expressed in media alone, although the difference was not significant. There
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was no difference in the expression of CD25 in the CD8+ T cell compartment between
the premalignant lesion cell and HNSCC cell environments. In the CD4 + T cell
compartment, the percentage of cells expressing the early activation marker CD69 in
cultures with HNSCC cell-conditioned media was significantly decreased compared to
cultures in media alone. In the CD8+ T cell compartment, the percentage of CD69+ cells
was significantly increased after culture with premalignant lesion cell-conditioned media
compared to culture with HNSCC cell-conditioned media or media alone. Further
analysis of CD69 expression revealed an increased percentage of CD69hi-expressing cells
among CD4+CD69+ and CD8+CD69+ T cells in cultures with premalignant lesion cell
supernatant compared to cultures with HNSCC cell supernatant or media alone,
suggesting that the premalignant lesion environment induces a population of highly
activated cells in both the CD4+ and CD8+ T cell compartments (gating strategy and
graphical results shown in Figure 3.7c,e). These data confirm the above described
cytokine analyses by showing that the immune environment shaped by premalignant
lesion cells is more stimulatory compared to the environment shaped by HNSCC cells
and induces a greater percentage of activated, CD4+ T cells expressing CD25 and a
greater percentage of CD4+ and CD8+ T cells expressing high levels of CD69.
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Fig. 3.6 Premalignant lesion cell-conditioned media elicits increased expression
of CD25 on CD4+ T cells and CD69 on CD4+ and CD8+ T cells, compared to
HNSCC cell-conditioned media or media alone. Representative results (a,c) and
graphical representation (b,d) of flow cytometric staining of spleen cells from
control C57BL/6 mice cultured with media alone, premalignant lesion
cell-conditioned media, or HNSCC cell-conditioned media for 72 h. Data show
staining of spleen cells from 3 independent experiments, run in duplicate. Graphical
results of the percentage of CD69hi populations among CD4+CD69+ cells and
CD8+CD69+ cells gated in (d) are shown in (e). Data represent mean + SEM.
*p<0.05 **p<0.01 ***p<0.001 ~p=0.056 (2-tailed Student’s t-test).
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Cervical lymph node cells produce increased levels of Th1-, Th2-, and Th17-associated
cytokines and proinflammatory mediators in the presence of premalignant lesion cell
supernatant
In the 4-NQO model, cervical lymph nodes drain the oral cavity and therefore
house immune cells that directly infiltrate the developing lesions and tumors [95, 97, 98,
100]. To investigate how immune mediators produced by premalignant lesion cells and
HNSCC cells impact on cytokine production by immune cells in the draining lymph
nodes of the developing lesions or tumors, cervical lymph node cells were cultured with
media conditioned by premalignant lesion cells or HNSCC cells and supernatants were
collected for analysis by CBA. As shown in Figure 3.7, in the presence of premalignant
lesion cell supernatant, cervical lymph node cells produced increased levels of
Th1-associated cytokines compared to cervical lymph node cells cultured in the presence
of HNSCC cell supernatant or media alone. This included increases in cervical lymph
node cell production of IL-2, IFN-γ, and TNF-α in the presence of premalignant lesion
cell supernatant compared to lymph node cell production of these Th1-type cytokines in
the presence of HNSCC cell supernatant or media alone. A similar trend was found for
Th2-associated cytokines, although the overall levels of Th2-associated cytokines were
lower than Th1-associated cytokines. In the presence of premalignant lesion cellconditioned media, cervical lymph node cells secreted increased levels of IL-4 and IL-6
compared to cervical lymph node cells in the presence of HNSCC cell-conditioned media
or media alone.
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Similarly, cervical lymph node cells produced increased levels of the Th17
cell-associated cytokine IL-17A and other proinflammatory mediators in the presence of
premalignant lesion cell-conditioned media compared to levels produced by lymph node
cells cultured with HNSCC cell-conditioned media or fresh media alone (Figure 3.7). The
level of IL-17A produced by spleen cells in the premalignant lesion cell environment was
higher than the level produced by spleen cells in the HNSCC cell environment or media
alone. Cervical lymph node cells produced significantly higher levels of the chemokines
MIP-1α and MIP-1β in the presence of premalignant lesion cell-conditioned media
compared to when cultured in HNSCC cell-conditioned media or media alone, suggesting
the premalignant lesion environment supports a more proinflammatory macrophage
response compared to the HNSCC environment. The level of macrophage-supporting
G-CSF was also higher in the supernatant of cervical lymph node cells cultured with
premalignant lesion cell-conditioned media compared to when cultured with HNSCC
cell-conditioned media or media alone. Overall, premalignant lesion cell supernatant
elicits increased production of proinflammatory mediators from cervical lymph node cells
compared to what is elicited by HNSCC cell supernatant.
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Fig. 3.7 Cervical lymph node cells release increased levels of Th1-, Th2- and
Th17-associated cytokines and proinflammatory mediators in the presence of
premalignant cell-conditioned media compared levels released by lymph node
cells in the presence of HNSCC cell-conditioned media or fresh media alone.
Cervical lymph node cells were extracted from control C57BL/6 mice and cultured
with premalignant lesion cell-conditioned media, HNSCC cell-conditioned media or
media alone for 72 h. Cell cultures were restimulated with PMA/ionomycin for the
last 4 h of culture and supernatants were collected for cytokine analyses by CBA.
Data shown represent mean + SEM of three independent experiments, each performed
in duplicate. *p<0.05 **p<0.01 ***p<0.001 ****p<0.0001 (2-tailed Student’s t test).
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CHAPTER 4: ADMINISTRATION OF INDOMETHACIN TO PREMALIGNANTLESION BEARING MICE

Aim 2: To prevent the immune skewing and tumor progression in 4-NQO-treated
mice by inhibiting PGE2 production at the premalignant lesion stage.

4.1 Introduction
The five-year survival rate for HNSCC patients remains at 50% [2]. Treatment for
HNSCC patients is significantly complicated by immunosuppression and, in many cases,
the traditional routes of therapy, including surgical resection and chemo-radiation, are
ineffective at completely eliminating the tumor [1, 2, 20, 26, 28]. Furthermore, due to the
location of primary tumors on the head and neck region and the effect of major surgery in
this region, patient quality of life is often significantly decreased. There exists a critical
need for more effective therapies, and focus has recently shifted to immunotherapies to
reduce the burden of primary tumors and prevent recurrence.
The goal of any effective immunotherapy is to activate the patient’s own immune
system to eradicate tumor. HNSCC tumors use a variety of mechanisms to evade the
immune response, including recruitment of immunosuppressive cells, inhibition of
cytotoxic T cells, and secretion of factors such that dampen the immune response at the
tumor site [10, 28, 31, 32, 35, 106]. One of the factors that is upregulated in the HNSCC
tumor environment is PGE2. While PGE2 is a proinflammatory mediator, it has also been
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shown to directly inhibit T cell function, recruit immunosuppressive cells to the tumor
site, skew dendritic cells toward myeloid-derived suppressor cells, and increase tumor
growth [26, 46-49, 52, 53, 55, 60, 61]. Increased expression of COX-2, the enzyme
responsible for increased PGE2 production by HNSCC tumors, is correlated with a worse
prognosis in patients, suggesting that PGE2’s role in dampening the immune response at
the tumor site plays a role in a patient’s clinical status [20, 26, 28, 60]. Previous studies
have shown that treating HNSCC cells with COX inhibitors results in increased apoptosis
and decreased growth of tumor cells [61]. In multiple models of murine and hamster head
and neck cancer, administration of the COX-2-specific inhibitor celecoxib resulted in
decreased tumor cell growth and angiogenesis [61-63]. These studies suggest that COX
inhibition may be beneficial as a therapy for HNSCC patients. One retrospective study
showed that HNSCC patients who had been on a regimen of COX inhibitors prior to
surgery had increased survival rates compared to patients who had not [65], although
neither the type of COX inhibitor nor the dosage was controlled for in this study. Several
clinical trials have shown that administration of celecoxib to HNSCC patients as an
adjuvant therapy resulted in significantly improved response rates [66-68]. The impact of
COX inhibition on the immune response in HNSCC patients, however, has not been
extensively studied. One study showed that preoperative administration of Rofecoxib,
another COX-2-specific inhibitor, resulted in improved monocyte function, but the
impact on T cell function or overall immune status, was not investigated [64].
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There remains a gap in our knowledge of how COX inhibition affects the immune
response in HSNCC patients, and specifically, how COX inhibition impacts on immune
cell reactivity as premalignant lesions progress to tumor. Our preliminary studies in the
4-NQO mouse model of oral carcinogenesis have shown that, despite the broad-range
immune stimulatory and inflammatory environment of premalignant oral lesions, PGE2 is
produced in much higher levels by premalignant lesion cells compared to what is
produced by HNSCC cells This suggests that PGE2 may be playing a previously
unappreciated immune-modulatory role as premalignant lesions progress to tumor. There
may be a critical window, such as during the premalignant lesion stage, in which COX
inhibitors can be administered to activate and direct a patient’s immune system to
eradicate the developing tumor or to slow tumor progression. The hypothesis of the
current study is that inhibiting PGE2 production at the premalignant lesion stage will
skew immune cells to a Th1-associated phenotype, leading to improved clinical outcomes
and slowing progression to tumor.
The focus of this study is to investigate whether inhibiting PGE 2 production by
premalignant lesions results in increased activation of immune cells and if this plays a
role in the clinical outcome of mice with 4-NQO-induced oral lesions. Treating
premalignant lesion cells with indomethacin, a pan-COX inhibitor, resulted in increased
induction of immune cell production of Th1-associated cytokines in vitro. To advance
studies to be clinically relevant, indomethacin was administered to mice with 4-NQOinduced premalignant lesions and the phenotype of immune cells infiltrating the cervical
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lymph nodes and progression to tumor were observed (timeline shown in Figure 4.1).
Mice receiving indomethacin at the premalignant lesion stage had significantly improved
clinical outcomes compared to mice receiving diluent control treatment. The cervical
lymph nodes and spleens of mice receiving indomethacin were characterized by
increased IFN-γ expression compared to what was seen in mice receiving control
treatment, suggesting that indomethacin plays a role in skewing immune cells to a Th1associated phenotype, which are part of a more effective antitumor response.

Figure 4.1 Timeline of indomethacin administration
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4.2 Materials and Methods
Oral HNSCC carcinogenesis
Five mg/mL 4-NQO in propylene glycol stock was diluted into the drinking water
at a final concentration of 50 μg/mL and administered to 2-month-old female C57BL/6
mice (Charles Rivers Laboratory, Wilmington, MA, USA) until the development of
premalignant oral lesions (6–8 weeks) or HNSCC (12–16 weeks). To monitor lesion
development, mice were examined endoscopically weekly using a Stryker 1.9 mm × 30°
endoscope and images were taken using a Stryker 1088 camera (Kalamazoo, MI, USA).
During the procedure, mice were sedated with inhaled isoflurane (Piramal Healthcare,
Boise, ID, USA).

Culture medium
Cell culture media consisted of 1X DMEM (Life Technologies, Grand Island,
NY, USA) containing 4.5 g/L D-glucose and L-glutamine, supplemented with 10% fetal
bovine serum (FBS, Sigma, St. Louis, MO, USA) and 1X antibiotic antimycotic solution
(Sigma, St. Louis, MO, USA) containing penicillin, streptomycin and amphotericin B. To
establish cell lines from premalignant lesions and HNSCC tumors, culture media was
supplemented with 2X antibiotic antimycotic solution for the first 2 weeks of culture.

Premalignant lesion and HNSCC cell lines
Primary cell lines were established by excising the tongues of premalignant or
HNSCC-bearing mice at the appropriate stage, as defined through histopathological analysis
Chapter 4

67

Administration of Indomethacin to
Premalignant Lesion-bearing Mice

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
by the oral pathology section in the Center for Oral Health Research at the Medical
University of South Carolina. Premalignant lesions or HNSCC were excised from the
tongues of 4-NQO treated mice. To establish cell lines, premalignant lesions or HNSCC
tumors were washed several times with PBS and antibiotic/antimycotic solutions containing
100 mg/mL penicillin, 100 mg/mL streptomycin, and 200 mg/mL neomycin. Premalignant
lesions or HNSCC tumors were plated on 60 mm tissue culture dishes in DMEM media
supplemented with 10% FBS and penicillin/streptomycin/amphotericin B and cultured for
two weeks at 37º C, replacing the media twice per week. After this period, adhering
premalignant lesion or carcinoma cells were removed and cultured in 75 cm2 flasks in fresh
media at 37° C, replacing the media twice per week. Prior to defining cells as
premalignant or HNSCC, their epithelial phenotype was confirmed as well as uniformity
of their microscopic and growth characteristics. To detach adherent cells, they were
trypsinized, washed, and resuspended in fresh medium.

Spleen processing
Spleens were harvested from control C57BL/6 mice and homogenized using a
glass homogenizer. Cells were passed through a 70 μm cell strainer (BD Falcon, San
Jose, CA, USA) and rinsed with HBSS. Red blood cells were lysed by adding ACK
Lysing Buffer (Lonza, Walkersville, MD, USA) for 3 min. Splenocytes were then washed
twice with HBSS. Cell number was determined by counting cells excluding trypan blue
using a hemocytometer.
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Indomethacin treatment of premalignant lesion cells and HNSCC cells
Premalignant lesion cells and HNSCC cells were cultured for 24 h at 37° C at
1×106 cells/well in 12-well tissue culture plates in fresh media with or without 6 μg/mL
indomethacin, as previously described [107]. Supernatants were collected for culture with
spleen cells. To serve as a control for indomethacin treatment, spleen cells were cultured in
fresh media with 6 μg/mL indomethacin.

Spleen cell cultures with indomethacin-treated premalignant lesion and HNSCC cell
supernatants
Spleen cells from control C57BL/6 mice were cultured for 72 h at 37° C with
supernatants collected from indomethacin-treated premalignant lesion cells and HNSCC
cells, respectively, at 1×106 cells/well in 12-well anti-CD3-coated tissue culture plates at a
dilution of 1:2 in fresh media containing 30 IU recombinant mouse IL-2. Controls consisted
of splenocytes cultured for 72 h at 37° C in fresh medium, with or without 6 μg/mL
indomethacin. Supernatants were collected and the levels of cytokines, chemokines, or
prostaglandins produced by spleen cells were quantitated using CBAs and ELISA. The
cytokine profile and activation status of spleen cells was analyzed by CBA and flow
cytometric staining.

Cytokine bead array
All reagents used for the cytokine bead array are from BD Biosciences unless
otherwise specified. The levels of IFN-γ, IL-2, IL-17A, IL-4, IL-6 and IL-10 in cell cultures
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were determined using a mouse cytometric bead array (CBA) Th1/Th2/Th17 cytokine kit.
Levels of IL-1α, IL-1β, IL-13, IL-12p70, IL-9, GM-CSF, G-CSF, MIG, MCP-1, MIP-1α,
MIP-1β and RANTES in cell cultures were determined using cytometric bead array flex sets
for the individual cytokines according to the manufacturer’s instructions. A FACS Canto
(BD Biosciences, San Jose, CA, USA) flow cytometer was used to quantify cytokine
profiles and relative amounts of each cytokine were analyzed using FCAP Array
Software (manufactured by Soft Flow Hungary Ltd. for BD Biosciences, San Jose, CA,
USA). In experiments where premalignant lesion or HNSCC supernatants were added to
spleen cell cultures, cytokine levels in total spleen cell supernatants were adjusted for
baseline levels in premalignant or HNSCC supernatants.

Indomethacin treatment of 4-NQO-treated mice
Two-month-old female C57BL/6 mice (Charles Rivers Laboratory, Wilmington,
MA, USA) were administered 50 μg/mL 4-NQO in their drinking water until the
development of premalignant oral lesions (8 weeks), as determined by weekly endoscopy
of the oral cavities. At this time point, one group of C57BL/6 control mice (5 mice) and
one group of premalignant lesion-bearing mice (5 mice) were euthanized and tongues and
cervical lymph node cells were harvested for analysis. To the remaining premalignant
lesion-bearing mice, 4-NQO water was removed and replaced with drinking water
containing either 30 μg/mL indomethacin (10 mice) or diluent (1% ethanol) control (10
mice) [108]. Oral cavities were endoscopically monitored weekly for the development of
HNSCC using a Stryker 1.9 mm × 30° endoscope. Lesions were counted and scored
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blindly every 10 days and the development of tumors was documented using a Stryker
1088 camera. Six and twenty weeks after beginning indomethacin or diluent control
treatment one group of mice receiving indomethacin (5 mice) and one group of mice
receiving diluent control (5 mice) were sacrificed and tongues and cervical lymph nodes were
harvested for analysis. A group of age-matched untreated C57BL/6 control mice were also
sacrificed at these time points and tongues and cervical lymph nodes harvested for analysis.

Lesion scoring
As part of the endoscopic exam performed every 10 days, the total number and
gross pathologic score of tongue lesions in 4-NQO-treated mice receiving either
indomethacin or diluent control were blindly assessed and recorded as previously
described [100, 109]. Lesions were scored on a 1-4 scale, with 1 indicating a flat macule,
2 indicating a raised papule, 3 indicating a raised plaque, and 4 indicating a grossly
exophytic lesion.

Cervical lymph node processing and culture
Cervical lymph nodes were harvested from experimental and control C57BL/6
mice at designated time points, as described in individual experiments. Cervical lymph
nodes were homogenized using a Stomacher 80 homogenizer (Seward) set on high for 90
sec. Cells were then passed through a 70 μm cell strainer (BD Falcon, San Jose, CA,
USA) and rinsed with HBSS. Cell number was determined by counting cells excluding
trypan blue using a hemocytometer. Cells were cultured in 12-well anti-CD3-coated
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tissue culture plates at 1X106 cells/well in fresh media for 72 h at 37º C. Supernatants
were collected (500 μL) from each well for analysis by CBA. Cells were then
restimulated with 2 μL/mL Cell Stimulation Cocktail (eBioscience, PMA/ionomycin) and
0.6 μL/mL GolgiStop (BD Biosciences) for the last 4-6 h of culture at 37º C. Cells were
gently collected from tissue culture plates with 25 cm cell scrapers (Sarstedt, Inc.,
Newton, NC, USA), washed once with stain buffer, and transferred to polystyrene tubes
at 1X106 cells/tube for flow cytometric analysis.

Flow cytometric analysis of cells
All antibodies and reagents for this section are from BDBiosciences unless
otherwise stated. Spleen cells or cervical lymph node cells were processed to a single cell
suspension in polystyrene tubes at 1X106 cells/tube and were resuspended in 300 μL FACS
block buffer, containing 2% FBS in sterile 1X PBS, at 4º C for 15 min and centrifuged at
1000 rpm for 5 min. Cells were then incubated in 10 μL Fc block, containing antiCD16/CD32 antibody at a 1:100 dilution in sterile 1X PBS, at 4º C for 10 min to block
nonspecific antibody binding to the cell surface. Cells were washed twice in stain buffer
(BD Biosciences), resuspended in 1 mL cold BD Cytofix, and incubated for 20 min at 4º
C. Cells were centrifuged, washed twice in 1 mL stain buffer, resuspended in 1 mL BD
Perm/Wash Buffer and incubated for 15 min at room temperature. Cells were then
centrifuged, resuspended in 50 μL BD Perm/Wash Buffer and incubated for 30 min at
room temperature with equal concentrations of antibodies or appropriate isotype controls:
FITC CD4, APC CD8a, PerCP-Cy5.5 IFN-γ and PE CD69. Cells were washed twice in
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1 mL BD Perm/Wash Buffer and resuspended in 400 μL stain buffer for analysis of
extent and frequency of positive cells on a FACS Canto flow cytometer.

Tongue processing and culture
Three tongues per group of mice (control untreated mice or premalignant lesionbearing mice treated with diluent control or indomethacin) were harvested for analysis of
PGE2 levels by ELISA at the designated timepoints. After extraction, each tongue was
minced and enzymatically digested using 100 μg/mL of complete liberase cocktail
(Roche, Indianapolis, IN, USA) in 10 mL HBSS (Life Technologies, Grand Island, NY,
USA) at 37º C for 4 h. Tissue was resuspended in 1 mL sterile PBS and lysed using an
ultrasonic processor for 2 min. on ice. For each dissociated tongue, PGE2 levels were
standardized to total protein. Total protein was quantitated using a BCA protein assay kit
(Thermo Scientific, Rockford, IL, USA).

Prostaglandin E2 ELISA
To quantify PGE2 in tongue tissue, a competitive ELISA was performed
according to the manufacturer’s instructions (Pierce Biotechnology, Rockford, IL, USA).
Tongue tissue lysates were diluted 1:50 for analysis. Optical density at 405 nm was
measured using a Spectra Max M2 plate reader. Concentrations of PGE2 were determined
using SoftMax Pro 5.4.2 plate reader software. A standard concentration curve was
generated for each independent experiment. Tongue lysate samples were tested in
duplicate for 3 mice/group.
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Statistical analyses
Data were reported using the mean as a measure of central tendency + standard
error of the mean. To compare one variable condition between groups, a one-way
ANOVA analysis was initially performed (GraphPad Prism version 6.03 for Windows,
GraphPad Software, La Jolla, CA, USA). If differences were identified by the ANOVA
analysis, a two-tailed Student’s t test or Mann-Whitney U test was then performed to
determine significance of differences between each of two groups (ex.: control vs.
premalignant, control vs. HNSCC, premalignant vs. HNSCC, indomethacin vs. diluent
control) using GraphPad Prism version 6.03. Significance was reported in the 95%
confidence interval.
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4.3 Results
Indomethacin-treated premalignant lesion cells are increased in their capacity to skew
spleen cell cytokine production
One mechanism by which PGE2 impacts on immune reactivity in the tumor
environment is by inhibiting the production of Th1-associated cytokines by T cells [4649]. Inhibiting PGE2 production in a model of lung carcinoma resulted in a skewing of
cytokine production by resident immune cells towards a more Th1-type phenotype
characterized by increased IL-12 production, leading to decreased tumor growth [71]. To
analyze how inhibiting PGE2 production impacts on cytokine production by immune cells
in the premalignant lesion environment, and how this compares to the HNSCC
environment, spleen cells from control C57BL/6 mice were cultured with media
conditioned by supernatants collected from indomethacin-treated premalignant lesion
cells or HNSCC cells.
As shown in Figure 4.1 below, treatment of both premalignant lesion cells and
HNSCC cells with indomethacin, a pan-COX inhibitor, significantly decreased PGE 2 in
cell culture supernatant after 24 hours. This demonstrates that indomethacin effectively
inhibited COX enzymes in these cell cultures. Indomethacin treatment of premalignant
lesion cells significantly increased their induction of spleen cell production of
Th1-associated IL-2, whereas indomethacin treatment of HNSCC cells had no effect on
the induction of spleen cell production of IL-2. Indomethacin treatment of premalignant
lesion cells also increased their induction of spleen cell production of IFN-γ and IL-6,
although the differences were not significant. Similar to what was observed with IL-2,
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indomethacin treatment of HNSCC cells has no effect on the induction of IFN-γ or IL-6
production by spleen cells. These data suggest that inhibiting PGE2 production by
premalignant lesion cells may elicit increased production of Th1-type cytokines by
immune cells. Interestingly, supernatants from indomethacin-treated premalignant lesion
cells also led to increased spleen cell production of the Th2-associated cytokine IL-10
compared to exposure to supernatants from premalignant lesion cells that were not treated
with indomethacin, suggesting that PGE2 might be playing a role in triggering Th2mediated immunity as well as Th1-mediated immunity. However, the pro-tumoral vs.
anti-tumoral implications of indomethacin are not clear. Indomethacin treatment of both
premalignant lesion cells and HNSCC cells resulted in decreased production of IL-17A
by spleen cells, suggesting that in both the premalignant lesion and tumor environments,
PGE2 plays a role in maintaining Th17 cells or directly promotes IL-17A production.
Treatment of premalignant lesion cells with indomethacin did not alter spleen cell
expression of the IL-2 receptor CD25 or the early activation marker CD69 (data not
shown). The given data show that indomethacin treatment of premalignant lesion cells
skewed cytokine production by spleen cells towards a Th1-type response, which has been
shown to be more effective against tumor.
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Fig. 4.2 Pretreatment of premalignant lesion cells with indomethacin skews
cytokine production by splenocytes, leading to increased production of Th1associated IL-2 and decreased production of Th17-associated IL-17A. (a)
Premalignant lesion cells and HNSCC cells were plated at 1X106 cells/well and
treated with 6 μg/mL indomethacin for 24 h. The levels of PGE2 in cell supernatants
were analyzed by ELISA. (b) Spleen cells from control C57BL/6 mice were cultured
for 72 h with media conditioned by supernatants from premalignant lesion cell or
HNSCC cell cultures that remained untreated or were previously treated with 6 μg/mL
indomethacin. Supernatants were collected for cytokine analysis by CBA. Cytokine
levels were standardized to levels produced by spleen cells in media alone and data is
shown as fold change/control. Data represent 5 independent experiments, each run in
duplicate. Data represent mean + SEM. *p<0.05 **p<0.01 ***p<0.001
****p<0.0001 (2-tailed Student’s t-test).
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Administration of indomethacin to mice with 4-NQO-induced premalignant lesions
results in an improved clinical response compared to diluent control treatment
The goal of any effective immunotherapy is to improve clinical outcome. The
current study aimed to stimulate immune cell reactivity and slow progression to tumor by
administering indomethacin to mice at the premalignant lesion stage. To monitor the
development of premalignant lesions to HNSCC in mice treated with indomethacin vs.
diluent control, mice were endoscoped every 10 days, beginning at the premalignant
lesion stage. The lesions were scored on a 1-4 scale, with 1 representing a flat macule,
and 4 representing a grossly exophytic tumor. As shown in Figure 4.3a below, mice
receiving indomethacin treatment beginning at the premalignant lesion stage had a
significantly better overall clinical outcome compared to diluent control mice. At the
endpoint of the study (day 139, about 20 weeks post-initiation of treatment), the average
lesion score for mice receiving indomethacin was 1.9, whereas the average lesion score
for mice receiving diluent control was 3.4. Differences in clinical outcome were more
striking at later time points, as shown in Figure 4.3. There were no significant differences
in lesion stage between the diluent control and indomethacin groups until the last time
point (day 139 post-initiation of treatment), although by day 104, the average lesion score
for mice receiving diluent control treatment (2.5) was higher than mice receiving
indomethacin treatment (2.1). By the endpoint of the study (day 139) two mice in the
diluent control group progressed to advanced HNSCC (4), bearing exophytic tumors,
whereas no mice in the indomethacin group progressed to this stage during the study.
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Furthermore, 4 out of 5 mice in the diluent control group had lesions scores of 3 or higher
at the endpoint of the study, compared to one mouse in the indomethacin group. These
data show that administering indomethacin to mice with 4-NQO-induced premalignant
lesions improves clinical outcome and slows progression to HNSCC.
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Fig. 4.3 Administering indomethacin to mice with 4-NQO-induced premalignant
lesions improves clinical outcome and slows progression to HNSCC. (a)
Indomethacin or diluent control was administered in the drinking water of mice with
4-NQO-induced premalignant oral lesions. Oral cavities of mice were endoscoped
every 10 days and lesions were scored 1-4. Lesion scores for each mouse at
representative time points are shown in (b). Images of the oral cavity of a
representative mouse from each group are shown in (c). Lesion score data represent
mean + SEM. Shown in (b) and (c) are scores for mice endoscoped at baseline and at
days 13 (1.9 wks), 33 (4.7 wks), 70 (10 wks), 104 (14.9 wks) and 139 (19.9 wks) after
initiating indomethacin treatment. *p<0.05 (Mann-Whitney U test).
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Administration of indomethacin to mice with 4-NQO-induced premalignant lesions leads
to increased activation of cervical lymph node cells 20 weeks post-onset of treatment,
compared to that of diluent control treatment
Since the above studies showed an improved clinical response in mice receiving
indomethacin beginning at the premalignant lesion stage and other studies have shown
that inhibiting PGE2 leads to increased immune reactivity in the tumor environment [71],
we sought next to investigate whether indomethacin treatment impacted on immune cell
reactivity in our model. To investigate whether indomethacin treatment of mice with
premalignant lesions skews cytokine production by immune cells in vivo, cervical lymph
node cells were extracted from 4-NQO-treated mice receiving indomethacin or diluent
control treatments 6 weeks and 20 weeks post-onset of treatment and immunostained by
flow cytometry. As shown in Figure 4.4a below, the percentage and total number of T
cells expressing IFN-γ was not significantly different between the indomethacin and
diluent control treatment groups 6 weeks post-onset of treatment, although the total
number of CD8+IFN-γ+ T cells was increased in cervical lymph nodes of mice receiving
indomethacin compared to control C57BL/6 mice (p=0.059). The percentage of T cells
expressing the activation marker CD69 was not significantly different between the
indomethacin and diluent control treatment groups. At 20 weeks post-initiation of
treatment, the percentage of CD8+ T cells expressing IFN-γ in the cervical lymph nodes
of mice receiving indomethacin was increased compared to mice receiving diluent
control treatment, although the difference was not significant. The total number of
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CD8+IFN-γ+ T cells was increased in the cervical lymph nodes of mice receiving
indomethacin (p=0.066) and mice receiving diluent control treatment (p=0.034),
compared to control mice. Although the percentage of T cells expressing CD69 was not
different between the indomethacin and diluent control groups, the total numbers of
CD4+CD69+ and CD8+CD69+ T cells in the cervical lymph nodes of mice in the
indomethacin-treated group was increased compared to that in the untreated control
group, although the differences were not statistically significant (p=0.087, p=0.099).
While indomethacin treatment of mice with 4-NQO-induced premalignant lesions did not
result in statistically significant changes in the number of CD4 + or CD8+ cells expressing
IFN-γ, it caused a progressive tendency toward an increase in the number of CD8 + T cells
expressing IFN-γ and this tendency became more prominent with a more prolonged
period of indomethacin treatment. This suggests that indomethacin may play a role in
skewing cytokine production towards a Th1-type response by immune cells as
premalignant oral lesion progress to HNSCC.
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Fig. 4.4 Administering indomethacin to mice with 4-NQO-induced premalignant
lesions tends to increase the number of IFN-γ-expressing CD8+ T cells and CD69expressing CD4+ and CD8+ T cells at 20 weeks post-onset of treatment. Graphical
representation of flow cytometric staining of cervical lymph node cells extracted from
mice with 4-NQO-induced oral lesions receiving indomethacin or diluent control
treatment 6 weeks post-onset of treatment (a,b) and 20 weeks post-onset of treatment
(c,d). For intracellular cytokine staining, cells were stimulated with PMA/ionomycin
for the last 4 h of culture. Five mice were examined for each group per time point.
Total number of positive cells was calculated by multiplying percent positive cells by
the number of cervical lymph node cells for each mouse. Data represent mean + SEM.
*p<0.05 (2-tailed Student’s t-test).
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Administration of indomethacin to mice with 4-NQO-induced premalignant lesions
results in increased production of IFN-γ by spleen cells at 6 and 20 weeks post-onset of
treatment
Inhibiting PGE2 production has been shown to have immune stimulatory effects
in several animal models of cancer and chronic infection [71, 110-112]. The above
studies suggested a shift toward Th1-skewed immune cells in the cervical lymph nodes of
premalignant lesion-bearing mice treated with indomethacin. To determine if
indomethacin treatment induces a systemic Th1-type response in mice with
4-NQO-induced premalignant lesions, cytokine production by spleen cells from mice
receiving indomethacin or diluent control treatments was analyzed by cytokine bead
array. IL-2 production by spleen cells was not significantly affected by indomethacin or
diluent control treatments 6 weeks or 20 weeks post-onset of treatment (shown in Figure
4.5 below). However, the level of IFN-γ produced by spleen cells in mice receiving
indomethacin was increased compared to the level produced by spleen cells of diluent
control-treated mice. Importantly, while the level of IFN-γ produced by spleen cells in
mice receiving diluent control treatment was lower than the level produced by spleen
cells of untreated control mice, the level of IFN-γ produced by spleen cells in mice
receiving indomethacin was actually greater than control values, suggesting that
indomethacin does play a role in inducing a systemic, Th1-type response. The level of
IL-17A produced by spleen cells of mice receiving indomethacin was decreased
compared to the level produced by spleen cells of mice receiving diluent control and
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untreated control mice both 6 weeks and 20 weeks post-onset of treatment. The level of
proinflammatory TNF-α produced by spleen cells of indomethacin-treated mice receiving
indomethacin was increased compared to the levels produced by spleen cells of either
diluent-treated mice or from untreated mice 6 weeks post-onset of treatment (p=0.073),
although this difference was not evident 20 weeks post-onset of treatment. Overall, these
data suggest that administering indomethacin to mice with 4-NQO-induced oral lesions
can skew immune responses toward a systemic Th1-type response.
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Fig. 4.5 Administering indomethacin to mice with 4-NQO-induced premalignant
lesions increases spleen cell production of IFN-γ 6 weeks and 20 weeks post-onset
of treatment. Spleens from mice receiving indomethacin or diluent control
treatments were extracted at 6 weeks and 20 weeks post-onset of treatment. Spleen
cells were cultured for 72 h at 1X106 cells/well and supernatants were collected for
analysis by CBA. Five mice were examined for each group per time point. Spleen
cells from untreated C57BL/6 mice served as controls. Cytokine levels were analyzed
as fold change from values for controls. Data represent mean + SEM. *p<0.05
(2-tailed Student’s t-test).
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APPENDIX
Cervical lymph nodes of mice with 4-NQO induced premalignant lesions contain an
increased percentage of CD8+CD69+ cells compared to levels in control mice

Fig. S4.1 Cervical lymph nodes of mice with 4-NQO induced premalignant
lesions contain an increased percentage of CD8+CD69+ cells. Graphical
representation of flow cytometric staining of cervical lymph node cells extracted
from mice with 4-NQO-induced premalignant oral lesions. For intracellular cytokine
staining, cells were stimulated with PMA/ionomycin for the last 4h of culture. Five
mice were examined for each group per time point. Total number of positive cells
was calculated by multiplying percent positive cells by the number of cervical lymph
node cells for each mouse. Data represent mean + SEM. *p<0.05 (2-tailed Student’s
t-test).
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Administration of indomethacin to mice with 4-NQO-induced premalignant lesions
decreases levels of PGE2 in tongue tissue compared to levels in diluent control-treated
mice

Fig. S4.2 Administering indomethacin to mice with 4-NQO-induced
premalignant lesions decreases levels of PGE2 in tongue tissue 6 weeks post-onset
of treatment. Tongues from mice receiving indomethacin or diluent control
treatments were extracted at baseline, 6 weeks and 20 weeks post-onset of treatment.
Tongue tissue was mechanically and enzymatically digested using a liberase cocktail.
Tongue tissue was lysed and levels of PGE2 in lysates were determined by ELISA
after diluting samples 1:50. Levels of PGE2 were normalized to tissue protein levels.
Data represent 3 mice per group per time point, run in duplicate. Data represent mean
+ SEM. *p<0.05 (2-tailed Student’s t-test).
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Administration of indomethacin to mice with 4-NQO-induced premalignant lesions
results in an increase in total cervical lymph node cell count 6 weeks and 20 weeks
post-onset of treatment

Fig. S4.3 Administering indomethacin to mice with 4-NQO-induced
premalignant lesions increases the total number of cervical lymph node cells 6
and 20 weeks post-initiation of treatment. Cervical lymph nodes from mice
receiving indomethacin or diluent control treatments were extracted at baseline, 6
weeks and 20 weeks post-initiation of treatment. Cells were processed to single cell
suspensions and total number of trypan blue-excluding cells were counted. Data
represent 5 mice per group per time point. Data represent mean + SEM.
*p<0.05 (2-tailed Student’s t-test). The total number of cervical lymph node cells
in mice receiving diluent control treatment decreased from 6 to 20 weeks
post-initiation of treatment (^^p=0.07).
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Administration of indomethacin to mice with 4-NQO-induced premalignant lesions does
not impact on total number of CD4+ and CD8+ T cells within the cervical lymph nodes

Fig. S4.4 Administering indomethacin to mice with 4-NQO-induced
premalignant lesions does not impact on the total number of CD4 + or CD8+ T
cells within cervical lymph nodes. Graphical representation of flow cytometric
staining of cervical lymph node cells extracted from mice with 4-NQO-induced oral
lesions receiving indomethacin or diluent control treatment 6 weeks post-onset of
treatment (a) and 20 weeks post-onset of treatment (b). Five mice were examined for
each group per time point. Total number of positive cells was calculated by
multiplying percent positive cells by the number of cervical lymph node cells for each
mouse. Data represent mean + SEM. *p<0.05 **p<0.01 (2-tailed Student’s t-test).
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CHAPTER 5: GENERAL DISCUSSION
5.1 HNSCC Tumors Suppress Immune Cell Reactivity
HNSCC patients are characterized by immunosuppression, both systemically and
at the site of the tumor [8-12]. This remains one of the most challenging obstacles for
treatment and research has turned toward the development of immunotherapies aimed at
reactivating a patient’s immune system against the tumor. A critical part of developing an
effective immunotherapy is understanding the mechanisms by which developing HNSCC
tumors evade the immune response, which is the focus of the current study.
The process of tumor escape can be divided into three major phases [18, 113]. In
the first stage, elimination, transformed cells are recognized by circulating immune cells
and an inflammatory response is initiated to eliminate the dysplastic tissue. If any
remaining malignant cells persist, the equilibrium stage begins, which can last for many
years [18]. Though infiltrating immune cells recognize the dysplastic tissue and mount a
robust proinflammatory response, the tumor persists. The final stage, tumor escape, is
characterized by a loss of MHC expression by HNSCC cells and direct secretion of
immune-modulating factors [19-23]. Tumor-infiltrating T cells exhibit a number of
functional defects, including decreased proliferation in response to IL-2, decreased
expression of the CD3 ζ chain, and an imbalanced cytokine profile, marked by
significantly decreased IL-2 and IFN-γ secretion; in short, they exhibit a less activated
Th1 phenotype that is not effective against tumor [105, 106].
Primary tumors from HNSCC patients have been shown to secrete a panel of
immune-modulating factors, including IL-6, IL-10, GM-CSF, TGF-β and PGE2 [10, 20,
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28, 31, 34-36, 103, 104]. The role of each of these factors in the tumor environment is
complex, as factors typically associated with a proinflammatory immune response are
harnessed by the tumor for growth and angiogenesis. Tumor-secreted IL-6 and IL-10
promote a Th2-type response at the site of the tumor, which has been shown to be less
effective at eliminating a growing tumor and actually contributes to tumor growth by
recruiting a population of immunosuppressive T regulatory cells and skewing the
environment away from a more proinflammatory, antitumor Th1-type response [20, 2830]. Increased levels of GM-CSF at the site of HNSCC tumors have been associated with
an increased infiltration of MDSCs and a worse prognosis in patients [10, 35]. HNSCC
tumors also harness factors secreted by infiltrating immune cells. MDSC-derived IL-6
has been shown to promote tumor angiogenesis [33]. Even factors such as IFN-γ,
secreted by T cells, have been shown to contribute to Th17 cell differentiation and
increased tumor growth [114, 115]. Increased expression of COX-2, the enzyme
responsible for increased PGE2 production by HNSCC tumors, is also associated with
increased tumor growth and a poorer prognosis in patients [20, 26, 28, 36, 60]. Although
PGE2 contributes to neutrophil recruitment during the early stages of inflammation and
infection, it has been shown to directly inhibit CD8+ T cell function in the tumor
environment [39-41, 46-48]. It is well established that factors secreted by HNSCC cells
themselves play a critical role in shaping the immune response both at the tumor site and
systemically.
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5.2 Inflammatory Environment of Premalignant Lesions
While many studies have focused on the mechanisms by which established
HNSCC tumors evade an effective immune response, less focus has been given to what
the present study has shown to be a stage in which an inflammatory immune response is
active, and yet unsuccessful at eliminating, the dysplastic tissue, i.e. the premalignant
lesion stage. At what point does the inflammatory environment shaped by a robust
immune response turn towards a tumor-promoting mechanism? Is there a point, before
the tumor becomes established, that the immune response can be rescued to slow
progression to tumor?
A few studies have shown that premalignant oral lesions in patients are
characterized by increased levels of proinflammatory mediators, including IL-6 and
IL-17A, compared to HNSCC tumor tissue, but these studies are based on a low number
of patients and do not delve into the mechanism by which mediators released by the
lesions themselves impact on immune cell reactivity [72-74]. The current study uses the
4-NQO mouse model of oral carcinogenesis to investigate how the immune environment
of premalignant lesions differs from that of established HNSCC, and more specifically,
how factors secreted by premalignant lesion cells modulate the immune response and
how this interaction leads to persistence of the tumor vs. eradication of the dysplastic
tissue. Preliminary studies in the 4-NQO model have shown that the cervical lymph
nodes of premalignant lesion-bearing mice are characterized by increased numbers of
proinflammatory T cells (Th17 cells) and proinflammatory cytokines and chemokines
(IL-17A, MIP-1α, MIP-1β) compared to that seen in HNSCC-bearing and control mice,
suggesting that immune cells are more activated in the premalignant lesion environment
Chapter 5
96
General Discussion

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
[100]. The current study shows that tongue tissue from mice with 4-NQO-induced
premalignant lesions releases increased levels of Th1-and Th17-associated cytokines,
including IL-2, IFN-γ, TNF-α, and IL-17A compared to what is released from tongue
tissue from HNSCC-bearing and control mice. This indicates that the environment of
premalignant lesions, at the site of the tongue itself, is more proinflammatory compared
to the environment of established tumors, and suggests that the premalignant lesion
environment supports a more robust, Th1-type response compared to the HNSCC
environment.
When spleen cells from control C57BL/6 mice were cultured with media
conditioned by premalignant lesion-bearing tongue tissue, they produced significantly
increased levels of Th1- and Th2-associated cytokines, including IL-2, IL-4, and IL-10,
compared to spleen cells cultured with media conditioned by HNSCC-bearing tongue
tissue or media alone. This data indicates that the environment of premalignant
lesion-bearing tongue tissue is more immune stimulatory than HNSCC-bearing tongue
tissue. An interesting observation from this study is that after re-stimulation with
PMA/ionomycin, spleen cells produced comparable levels of both Th1- and
Th2-associated cytokines in both the premalignant lesion and HNSCC environments,
demonstrating that 1) Premalignant lesion-bearing tongue tissue is inherently more
immune stimulatory than HNSCC-bearing tongue tissue and 2) Spleen cells can be
stimulated to produce increased levels of these cytokines in the HNSCC environment, so
the cells are not inherently defective. It is somewhat perplexing that premalignant lesionbearing tongue tissue elicited increased production of both Th1-associated cytokines such
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as IL-2 and Th2-associated cytokines such as IL-10, which typically play a more
immunosuppressive role. This could suggest that the environment shaped by
premalignant lesions stimulates both Th1-type and Th2-type cells. Alternatively, the
increase in Th2-type cytokines may instead be the result of an initial dramatic increase in
Th1-type proinflammatory cytokines as a mechanism to “turn off” the cycle of
inflammation. In this way, the premalignant lesion state represents a battle of immune
cells secreting proinflammatory mediators to eliminate the dysplastic tissue against
immunosuppressive cells secreting immune inhibitory molecules to dampen
inflammation, which ultimately can lead to the establishment of HNSCC. As the current
study demonstrates, HNSCC-bearing tongue tissue does not elicit a significant Th1- or
Th2-type response from immune cells because by the time the tumor is established, the
battle has essentially been lost.
For the current study, a holistic in vitro approach was chosen to investigate how
mediators released by premalignant lesion-bearing vs. HNSCC-bearing tongue tissues
impact on spleen cell cytokine production. Because of the muscular nature of the tongue
and the mechanical and enzymatic methods of tongue digestion, harvesting a sufficient
population of live immune cells from tongue tissue for analysis of cytokine production is
not feasible. To account for secretion of cytokines and other immune mediators during
the digestion process, cytokine levels in spleen cell cultures were adjusted for baseline
levels in tongue tissue and all tongues were digested by identical means, so the results
could be interpreted clearly. Overall, the data demonstrate that the environment of a
developing premalignant lesion is more proinflammatory and elicits increased production
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of cytokines by immune cells compared to the environment of an established HNSCC
tumor. To further delve into the question of how the premalignant lesion vs. HNSCC
environment impacts on immune cell cytokine production, future studies could culture
isolated T cell subsets (CD4+, CD8+, Foxp3+) with media conditioned by tongue tissue
from premalignant lesion-bearing and control mice. This could more precisely tease out
the effects of the premalignant lesion environment skewing of CD4+ vs. CD8+ T cells and
offer insight into how the premalignant lesion environment impacts on proinflammatory
vs. immunosuppressive immune cells.
5.3 Mediators Secreted by Premalignant Lesion Cells
Dissecting how premalignant lesion cells and HNSCC cells themselves contribute
to the immune environment, and how this impacts on infiltrating immune cells, is
difficult for many reasons, one of which is the complexity of a developing tumor.
Premalignant lesions, as they develop into tumors, consist of a complex network of cells,
including epithelial cells, endothelial cells, fibroblasts, stromal cells, smooth muscle
cells, infiltrating immune cells, and cells that are transforming or have become malignant
[27].
The present study initiated the dissection of the premalignant lesion by
establishing primary cultures of premalignant lesion cells and HNSCC cells. These cells
were then used to define the immune mediators produced directly by premalignant lesion
and HNSCC cells as well as their impact on immune cells, as they also contribute to the
lesion and tumor environments. This study shows that premalignant lesion cells
established from mice with 4-NQO-induced lesions secrete significantly higher levels of
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several immune mediators, including MCP-1, RANTES, G-CSF, and PGE2, compared to
HNSCC cells. While the levels of these mediators were detectable in the supernatant of
HNSCC cells, as a few previous studies using human and murine HNSCC cell lines have
indicated [60, 102-104], they were detected in much higher levels in the supernatant of
premalignant lesion cells. These data bring to light a new observation: premalignant
lesion cells themselves produce high levels of several proinflammatory mediators. The
data suggest that the proinflammatory environment of premalignant lesion-bearing
tongues and increased infiltration of proinflammatory cells into the draining lymph nodes
of premalignant lesion-bearing mice observed in the 4-NQO model may be a direct
consequence of the environment set up by the premalignant lesion cells themselves.
To address the question of how proinflammatory mediators produced by
premalignant lesion cells might impact on immune cell cytokine production, spleen cells
or cervical lymph node cells were cultured with media conditioned by premalignant
lesion cells, HNSCC cells, or media alone. Premalignant lesion cell-conditioned media
elicited significantly increased production of innate proinflammatory mediators as well as
Th1-, Th2-, and Th17-associated cytokines by spleen cells and cervical lymph node cells
compared to HNSCC cell-conditioned media or media alone. Analysis by flow
cytometric staining showed that an increased percentage of CD4+ and CD8+ T cells
expressed IFN-γ and an increased percentage of CD8+ T cells expressed the early
activation marker CD69 in the presence of premalignant lesion-conditioned media
compared to what was expressed in the presence of HNSCC cell-conditioned media or
media alone. Furthermore, among both CD4+ and CD8+ T cells, a striking
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CD69hi- expressing population was observed in the presence of premalignant lesionconditioned media compared to what was observed in the presence of HNSCC cellconditioned media or media alone. The data shows that mediators released by
premalignant lesion cells skew immune cells toward a more activated, Th1-like
phenotype and also skew secretion of cytokines. This suggests that, at the cellular level,
premalignant lesion cells promote an activated, Th1-type response and set up a cycle of
inflammation at the site of the developing lesion.
The current study is based on cell cultures established from 4-NQO-induced
premalignant lesions or HNSCC tumors. Therefore, one consideration is whether
culturing the cells in vitro may lead to the production of a different panel of cytokines or
chemokines, which may not reflect the in vivo phenotype. To account for changes in
phenotype over the periods of culture and ensure consistency, the baseline levels of
cytokines and chemokines in collected supernatants were analyzed for each experiment.
The strength of establishing cell cultures from premalignant lesions and HNSCC tumors,
is that the cytokine and chemokine environment set up by the cells themselves (vs.
surrounding tissue), can be defined, which offers valuable insight into how premalignant
lesions might be modulating the immune response as they progress to tumor.
5.4 Role of PGE2 in the Progression of Premalignant Lesions to HNSCC
While the role of several immune mediators, such as PGE 2, has been studied in
the HNSCC environment, their role in the premalignant lesion environment has not been
defined. Previous studies have shown that PGE2 is upregulated in HNSCC tumors, and
increased levels of PGE2 have been associated with decreased levels of cytotoxic T cells
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increased levels of immunosuppressive cells at the tumor site [20, 28, 36, 60]. Increased
levels of COX-2, the inducible enzyme responsible for the increased PGE2 production, in
HNSCC tumors has also been associated with a worse prognosis in patients [26, 36]. In
other models of cancer, PGE2 has been shown to play an immunosuppressive role, by
promoting the secretion of Th2-associated IL-10, inhibiting production of IL-2 by T cells,
and supporting a population of immunosuppressive cells at the site of the tumor [46-53,
55]. In a model of lung carcinoma, inhibiting PGE 2 production led to a shift in cytokine
production by T cells towards a more Th1-type response and decreased tumor burden
[71].
In the current study, it was found that premalignant lesion cells secrete
significantly increased levels of PGE2 compared to HNSCC cells. This is paradoxical
given the immune stimulatory and inflammatory environment of premalignant lesions.
The current study aimed to determine the pro-tumor vs. anti-tumor role of PGE2 as
premalignant lesions progress to HNSCC. We hypothesized that inhibition of PGE2
production at the premalignant lesion stage may skew T cell cytokine production towards
a more Th1-type response, rather than a broad state of activation and inflammation, and
lead to improved clinical outcomes. In vitro, pretreatment of premalignant lesion cells
with indomethacin, a pan-COX inhibitor, resulted in increased induction of spleen cell
production of Th1-associated IL-2. Indomethacin treatment of HNSCC cells had minimal
effect on their induction of spleen cell cytokine production, suggesting that treatment at
the premalignant stage may be optimal to reactivate a Th1-type immune response.
Administration of indomethacin in the drinking water of mice with 4-NQO-induced
premalignant lesions resulted in reduced tumor burden and significantly improved
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clinical outcomes compared to that seen for diluent control-treated mice. At the endpoint
of the study, 4 out of 5 mice in the diluent control group had progressed to lesion scores
of 3 or higher (bearing raised plaques or grossly exophytic lesions or tumors) whereas
only one mouse had progressed to a lesion score of 3 in the indomethacin group. Analysis
of cervical lymph nodes revealed that CD8+ T cells in mice that had received
indomethacin expressed increased levels of IFN-γ compared to levels expressed by
lymph node cells of mice that had received diluent control treatment at 20 weeks
post-onset of treatment, although the results were not significant. Interestingly, the levels
of IFN-γ secreted by spleen cells were also significantly increased in mice that had
received indomethacin treatment compared to what was secreted by spleen cells of mice
that had received diluent control treatment, suggesting that indomethacin may play a role
in activating a systemic, Th1-type response that slows progression to tumor.
The results of this study offer insight into how PGE 2 modulates the immune
response at the premalignant lesion stage. Previous studies have looked at the effect of
inhibiting PGE2 production in tumors and have suggested that PGE 2 plays a role in
supporting T regulatory cells and promoting a Th2-type response [26, 38, 69-71]. The
current study suggests that PGE2 may also be playing an immunosuppressive role before
a tumor becomes established, as inhibiting PGE 2 production by premalignant lesion cells
resulted in increased production of IL-2 by spleen cells in vitro. However, inhibiting
premalignant lesion cell production of PGE 2 also led to an increased production of IL-10
in vitro, so the effect of indomethacin treatment cannot be classified singularly as
“pro-Th1.” The concurrent increase in IL-10 may be explained as a consequence of an
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initial increase in Th1-type cytokines, similar to what was observed with spleen cells
cultured with premalignant lesion cell-conditioned media alone. In vivo, administration of
indomethacin to mice beginning at the premalignant lesion stage resulted in significantly
improved clinical outcomes and increased production of IFN-γ by immune cells,
compared to what was seen for diluent control treatment. Interestingly, spleen cells from
mice that had received indomethacin secreted higher levels of IFN-γ at both 6 and 20
weeks post-onset of treatment compared to what was produced by spleen cells of mice
that had received diluent control treatment, suggesting that indomethacin could promote a
systemic, Th1-type response as lesions progress to tumor. Overall, the results suggest that
inhibiting PGE2 production at the premalignant lesion stage is advantageous to an
improved clinical outcome.
The current study adds valuable insight into the role of IL-17A, and Th17 cells, as
premalignant lesions progress to HNSCC. The role for Th17 cells in HNSCC
carcinogenesis, as with many other cancers, has not been completely defined. Some
studies have indicated they play a pro-tumoral role by promoting tumor angiogenesis and
growth in models of head and neck cancer as well as pancreatic neoplasia and skin cancer
[114, 116-118]. Other studies in both head and neck cancer and models of pancreatic
cancer suggest that they are part of a beneficial, antitumor response and promote tumor
cell apoptosis [116, 119]. PGE2 has been shown to play a role in sustaining Th17 cells in
the tumor environment through the IL-23 axis [120]. But how PGE2 impacts on Th17
cells in the premalignant environment has not been defined. By inhibiting PGE2
production at the premalignant lesion stage, the current study offers insight into the
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PGE2-Th17 cell axis as premalignant lesions progress to HNSCC. In vitro, inhibiting the
production of PGE2 by premalignant lesion cells and HNSCC cells led to decreased
production of IL-17A by spleen cells. This supports previous work implicating PGE 2 as a
key player in sustaining Th17 cells in the HNSCC environment, but also suggests a novel
role for PGE2 in promoting the secretion of IL-17A by Th17 cells, in both the
premalignant lesion and HNSCC environments. Furthermore, spleen cells from mice that
had received indomethacin at the premalignant lesion stage produced decreased levels of
IL-17A ex vivo compared to IL-17A production by spleen cells of mice that had received
diluent control treatment, suggesting that a decrease in PGE 2 in the lesion and developing
tumor environment may lead to a systemic decrease in IL-17A secretion by Th17 cells.
The current study offers evidence to support the hypothesis that Th17 cells play a
pro-tumoral role as premalignant lesions progress to tumor, as inhibiting PGE 2
production at the premalignant lesion stage reduced production of IL-17A by spleen cells
and led to significantly improved clinical outcomes.
Future studies with larger cohorts of mice will be necessary to investigate the role
of PGE2 in modulating Th17 cells as premalignant lesions progress to tumor. In the
current study, the number of cervical lymph node cells was not sufficient to detect levels
of cytokine section by CBA. To investigate the secretion of IL-17A by cells closer to the
site of the lesion and developing tumor, future studies could focus on the intracellular
expression of IL-17A by cervical lymph node cells over the course of indomethacin
treatment. Future studies might also investigate the role of IL-23 as a downstream
mediator of PGE2 in sustaining Th17 cells in the premalignant lesion environment by
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administering an IL-23 inhibitor along with a COX inhibitor to mice with 4-NQOinduced premalignant lesions.
One weakness of the current study is that the treatment groups consisted of five
mice each, making statistical analysis more difficult. Future studies based on larger
cohorts of mice will more clearly delineate differences in cytokine production between
treatment groups. This may also allow pooling of cervical lymph node cells among
treatment groups for analysis by CBA. In the current study, indomethacin, a pan-COX
inhibitor, was administered to mice through their drinking water, a mode of COX
inhibition that has been established in other mouse models of cancer [108, 121]. This
method is convenient, and in the case of oral cancer, allows treatment to be administered
at the site of the lesion and developing tumor. However, as shown in Supplementary
Figure S4.1, the levels of PGE2 in the supernatants of tongue tissue from mice that had
received indomethacin were moderately decreased 6 weeks post-onset of treatment
compared to mice that had received diluent control treatment and only minimally
decreased 20 weeks post-onset of treatment. This may be a consequence of the digestion
method, which damages the tissue and may promote the release of PGE 2 from endothelial
cells, fibroblasts, lesion cells, tumor cells and other cells in the tongue. Another
explanation is that because a majority of mice had progressed past the premalignant
lesion stage by the endpoint of the study and the level of PGE 2 produced by HNSCC
tumor cells is significantly reduced compared to the level produced by premalignant
lesion cells, differences induced by indomethacin treatment may not be as striking in the
later stages of tumor development. In the future, analyzing PGE 2 levels in the plasma
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may offer insight into how indomethacin impacts systemic levels of PGE 2 as
premalignant lesions progress to tumor. Future studies might also investigate how
COX-2-specific inhibition, through administration of celecoxib, impacts on immune cell
reactivity and clinical outcome as premalignant lesions progress to tumor. In this way, the
role of PGE2 in skewing the immune response at the premalignant lesion stage can be
further delineated.
5.5 Closing Remarks
Oral cancer is a unique malignancy, in that it can be diagnosed when tissue first
becomes dysplastic and presents as leukoplakias or erythroplakias developing on the
tongue and floor of mouth. By the time HNSCC becomes established, patients exhibit
local and systemic signs of immunosuppression, making treatment more difficult and
increasing the chance of recurrence. By diagnosing oral lesions before they develop into
established HNSCC and administering immunotherapies to activate a patient’s immune
response, treatment may become more effective for these patients.
The current study offers evidence that significant immune changes are occurring
before HNSCC becomes established, at the premalignant lesion stage. Premalignant
lesion cells established from mice with 4-NQO-induced lesions secrete a host of
mediators, including proinflammatory chemokines and PGE 2, and elicit increased
production of proinflammatory cytokines by immune cells compared to HNSCC cells.
Overall, the premalignant lesion environment is more immune stimulatory than the
HNSCC environment. The role of PGE2 in the premalignant lesion environment,
however, has not been previously defined. Previous studies have shown that HNSCC
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tumors are characterized by increased levels of PGE 2, which has been associated with a
decreased infiltration of T cells at the site of the tumor and a worse prognosis in patients.
Administration of COX inhibitors as adjuvant therapy to HNSCC patients has resulted in
improved clinical outcomes. However, the current study shows that PGE 2 is produced in
much higher levels by premalignant lesion cells compared to HNSCC cells, suggesting it
may be playing an immune-modulating role well before HNSCC is established.
Therefore, intervening with treatment to skew the response towards a more effective
Th1-type antitumor response may be more beneficial at the premalignant lesion stage,
when the battle against the dysplastic tissue is first being fought. The current study offers
evidence to support this view, as administration of indomethacin, a COX inhibitor, to
mice with 4-NQO-induced premalignant lesions led to increased production of Th1-type
cytokines by T cells, significantly improved clinical outcomes and slowed progression to
tumor. Overall, the current study shows that significant immune changes are occurring
much earlier in the progression of HNSCC than has been previously appreciated and
suggests that administration of immunotherapies, such as COX-2 inhibitors, at the
premalignant lesion stage may boost the immune response against tumor and improve
clinical outcomes for patients.

Chapter 5

108

General Discussion

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
LIST OF REFERENCES
1.

Duray, A., et al., Immune suppression in head and neck cancers: a review. Clin
Dev Immunol, 2010. 2010: p. 701657.

2.

Grandis, J.R., et al., Head and neck cancer: meeting summary and research
opportunities. Cancer Res, 2004. 64(21): p. 8126-9.

3.

Klein, J.D. and J.R. Grandis, The molecular pathogenesis of head and neck
cancer. Cancer Biol Ther, 2010. 9(1): p. 1-7.

4.

Jensen, S.B., et al., A systematic review of salivary gland hypofunction and
xerostomia induced by cancer therapies: management strategies and economic
impact. Support Care Cancer, 2010. 18(8): p. 1061-79.

5.

Vermorken, J.B. and P. Specenier, Optimal treatment for recurrent/metastatic
head and neck cancer. Ann Oncol, 2010. 21 Suppl 7: p. vii252-61.

6.

Tanvetyanon, T., et al., Prognostic factors for survival after salvage reirradiation
of head and neck cancer. J Clin Oncol, 2009. 27(12): p. 1983-91.

7.

Gilbert, H. and A.R. Kagan, Recurrence patterns in squamous cell carcinoma of
the oral cavity, pharynx, and larynx. J Surg Oncol, 1974. 6(5): p. 357-80.

8.

Bergmann, C., et al., T regulatory type 1 cells in squamous cell carcinoma of the
head and neck: mechanisms of suppression and expansion in advanced disease.
Clin Cancer Res, 2008. 14(12): p. 3706-15.

9.

Badoual, C., et al., Prognostic value of tumor-infiltrating CD4+ T-cell
subpopulations in head and neck cancers. Clin Cancer Res, 2006. 12(2): p. 46572.

10.

Young, M.R., et al., Increased recurrence and metastasis in patients whose
primary head and neck squamous cell carcinomas secreted granulocytemacrophage colony-stimulating factor and contained CD34+ natural suppressor
cells. Int J Cancer, 1997. 74(1): p. 69-74.

11.

Chikamatsu, K., et al., Relationships between regulatory T cells and CD8+
effector populations in patients with squamous cell carcinoma of the head and
neck. Head Neck, 2007. 29(2): p. 120-7.

109

List of References

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
12.

Drennan, S., et al., Increased frequency and suppressive activity of CD127(low/-)
regulatory T cells in the peripheral circulation of patients with head and neck
squamous cell carcinoma are associated with advanced stage and nodal
involvement. Immunology, 2013. 140(3): p. 335-43.

13.

De Stefani, A., et al., Improved survival with perilymphatic interleukin 2 in
patients with resectable squamous cell carcinoma of the oral cavity and
oropharynx. Cancer, 2002. 95(1): p. 90-7.

14.

Whiteside, T.L., et al., Evidence for local and systemic activation of immune cells
by peritumoral injections of interleukin 2 in patients with advanced squamous cell
carcinoma of the head and neck. Cancer Res, 1993. 53(23): p. 5654-62.

15.

Rojo, F., et al., Pharmacodynamic trial of nimotuzumab in unresectable
squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin
Cancer Res, 2010. 16(8): p. 2474-82.

16.

Mehra, R., R.B. Cohen, and B.A. Burtness, The role of cetuximab for the
treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol
Oncol, 2008. 6(10): p. 742-50.

17.

Ho, C., et al., Escalating weekly doses of cetuximab and correlation with skin
toxicity: a phase I study. Invest New Drugs, 2011. 29(4): p. 680-7.

18.

Schreiber, R.D., L.J. Old, and M.J. Smyth, Cancer immunoediting: integrating
immunity's roles in cancer suppression and promotion. Science, 2011. 331(6024):
p. 1565-70.

19.

Badoual, C., et al., Better understanding tumor-host interaction in head and neck
cancer to improve the design and development of immunotherapeutic strategies.
Head Neck, 2010. 32(7): p. 946-58.

20.

Young, M.R., Protective mechanisms of head and neck squamous cell carcinomas
from immune assault. Head Neck, 2006. 28(5): p. 462-70.

21.

Ferris, R.L., T.L. Whiteside, and S. Ferrone, Immune escape associated with
functional defects in antigen-processing machinery in head and neck cancer. Clin
Cancer Res, 2006. 12(13): p. 3890-5.

22.

Ogino, T., et al., HLA class I antigen down-regulation in primary laryngeal
squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res, 2006.
66(18): p. 9281-9.

110

List of References

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
23.

Grandis, J.R., et al., Human leukocyte antigen class I allelic and haplotype loss in
squamous cell carcinoma of the head and neck: clinical and immunogenetic
consequences. Clin Cancer Res, 2000. 6(7): p. 2794-802.

24.

Zeng, X., Q. Chen, and M. Nie, [The relationship of Fas and Fas L protein
expression in oral carcinogenesis]. Hua Xi Kou Qiang Yi Xue Za Zhi, 2003.
21(4): p. 259-62.

25.

Cho, Y.A., et al., Relationship between the expressions of PD-L1 and tumorinfiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncol, 2011.
47(12): p. 1148-53.

26.

Young, M.R., et al., Mechanisms of immune suppression in patients with head
and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer,
1996. 67(3): p. 333-8.

27.

Koontongkaew, S., The tumor microenvironment contribution to development,
growth, invasion and metastasis of head and neck squamous cell carcinomas. J
Cancer, 2013. 4(1): p. 66-83.

28.

Jewett, A., C. Head, and N.A. Cacalano, Emerging mechanisms of
immunosuppression in oral cancers. J Dent Res, 2006. 85(12): p. 1061-73.

29.

Bose, A., et al., Dysregulation in immune functions is reflected in tumor cell
cytotoxicity by peripheral blood mononuclear cells from head and neck squamous
cell carcinoma patients. Cancer Immun, 2008. 8: p. 10.

30.

Lathers, D.M., N.J. Achille, and M.R. Young, Incomplete Th2 skewing of
cytokines in plasma of patients with squamous cell carcinoma of the head and
neck. Hum Immunol, 2003. 64(12): p. 1160-6.

31.

Lu, S.L., et al., Overexpression of transforming growth factor beta1 in head and
neck epithelia results in inflammation, angiogenesis, and epithelial
hyperproliferation. Cancer Res, 2004. 64(13): p. 4405-10.

32.

Wahl, S.M., J. Wen, and N. Moutsopoulos, TGF-beta: a mobile purveyor of
immune privilege. Immunol Rev, 2006. 213: p. 213-27.

33.

Nitsch, S.M., R. Pries, and B. Wollenberg, Head and neck cancer triggers
increased IL-6 production of CD34+ stem cells from human cord blood. In Vivo,
2007. 21(3): p. 493-8.

34.

Chen, Z., et al., Expression of proinflammatory and proangiogenic cytokines in
patients with head and neck cancer. Clin Cancer Res, 1999. 5(6): p. 1369-79.
111

List of References

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
35.

Bronte, V., et al., Unopposed production of granulocyte-macrophage colonystimulating factor by tumors inhibits CD8+ T cell responses by dysregulating
antigen-presenting cell maturation. J Immunol, 1999. 162(10): p. 5728-37.

36.

Hambek, M., et al., Inverse correlation between serum PGE2 and T classification
in head and neck cancer. Head Neck, 2007. 29(3): p. 244-8.

37.

Liss, C., et al., Paracrine angiogenic loop between head-and-neck squamous-cell
carcinomas and macrophages. Int J Cancer, 2001. 93(6): p. 781-5.

38.

Kalinski, P., Regulation of immune responses by prostaglandin E2. J Immunol,
2012. 188(1): p. 21-8.

39.

Yu, Y. and K. Chadee, Prostaglandin E2 stimulates IL-8 gene expression in
human colonic epithelial cells by a posttranscriptional mechanism. J Immunol,
1998. 161(7): p. 3746-52.

40.

Nakayama, T., et al., Prostaglandin E2 promotes degranulation-independent
release of MCP-1 from mast cells. J Leukoc Biol, 2006. 79(1): p. 95-104.

41.

Weller, C.L., et al., Chemotactic action of prostaglandin E2 on mouse mast cells
acting via the PGE2 receptor 3. Proc Natl Acad Sci U S A, 2007. 104(28): p.
11712-7.

42.

Smith, R.J., Modulation of phagocytosis by and lysosomal enzyme secretion from
guinea-pig neutrophils: effect of nonsteroid anti-inflammatory agents and
prostaglindins. J Pharmacol Exp Ther, 1977. 200(3): p. 647-57.

43.

Aronoff, D.M., C. Canetti, and M. Peters-Golden, Prostaglandin E2 inhibits
alveolar macrophage phagocytosis through an E-prostanoid 2 receptor-mediated
increase in intracellular cyclic AMP. J Immunol, 2004. 173(1): p. 559-65.

44.

Canetti, C., et al., Activation of phosphatase and tensin homolog on chromosome
10 mediates the inhibition of FcgammaR phagocytosis by prostaglandin E2 in
alveolar macrophages. J Immunol, 2007. 179(12): p. 8350-6.

45.

Serezani, C.H., et al., Prostaglandin E2 suppresses bacterial killing in alveolar
macrophages by inhibiting NADPH oxidase. Am J Respir Cell Mol Biol, 2007.
37(5): p. 562-70.

46.

Walker, C., et al., Lymphokine regulation of activated (G1) lymphocytes. I.
Prostaglandin E2-induced inhibition of interleukin 2 production. J Immunol,
1983. 130(4): p. 1770-3.
112

List of References

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
47.

Rincon, M., et al., Prostaglandin E2 and the increase of intracellular cAMP
inhibit the expression of interleukin 2 receptors in human T cells. Eur J Immunol,
1988. 18(11): p. 1791-6.

48.

Kalinski, P., et al., IL-12-deficient dendritic cells, generated in the presence of
prostaglandin E2, promote type 2 cytokine production in maturing human naive T
helper cells. J Immunol, 1997. 159(1): p. 28-35.

49.

Kalinski, P., et al., Prostaglandin E2 induces the final maturation of IL-12deficient CD1a+CD83+ dendritic cells: the levels of IL-12 are determined during
the final dendritic cell maturation and are resistant to further modulation. J
Immunol, 1998. 161(6): p. 2804-9.

50.

Kalinski, P., et al., T-cell priming by type-1 and type-2 polarized dendritic cells:
the concept of a third signal. Immunol Today, 1999. 20(12): p. 561-7.

51.

Gustafsson, K., et al., Recruitment and activation of natural killer cells in vitro by
a human dendritic cell vaccine. Cancer Res, 2008. 68(14): p. 5965-71.

52.

Sharma, S., et al., Tumor cyclooxygenase 2-dependent suppression of dendritic
cell function. Clin Cancer Res, 2003. 9(3): p. 961-8.

53.

Sombroek, C.C., et al., Prostanoids play a major role in the primary tumorinduced inhibition of dendritic cell differentiation. J Immunol, 2002. 168(9): p.
4333-43.

54.

Heusinkveld, M., et al., M2 macrophages induced by prostaglandin E2 and IL-6
from cervical carcinoma are switched to activated M1 macrophages by CD4+
Th1 cells. J Immunol, 2011. 187(3): p. 1157-65.

55.

Obermajer, N., et al., Positive feedback between PGE2 and COX2 redirects the
differentiation of human dendritic cells toward stable myeloid-derived suppressor
cells. Blood, 2011. 118(20): p. 5498-505.

56.

Jonuleit, H., et al., Pro-inflammatory cytokines and prostaglandins induce
maturation of potent immunostimulatory dendritic cells under fetal calf serumfree conditions. Eur J Immunol, 1997. 27(12): p. 3135-42.

57.

Rieser, C., et al., Prostaglandin E2 and tumor necrosis factor alpha cooperate to
activate human dendritic cells: synergistic activation of interleukin 12 production.
J Exp Med, 1997. 186(9): p. 1603-8.

58.

Luft, T., et al., Functionally distinct dendritic cell (DC) populations induced by
physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of
specific DC subsets. Blood, 2002. 100(4): p. 1362-72.
113
List of References

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
59.

Scandella, E., et al., Prostaglandin E2 is a key factor for CCR7 surface expression
and migration of monocyte-derived dendritic cells. Blood, 2002. 100(4): p. 135461.

60.

Abrahao, A.C., et al., A role for COX2-derived PGE2 and PGE2-receptor
subtypes in head and neck squamous carcinoma cell proliferation. Oral Oncol,
2010. 46(12): p. 880-7.

61.

Kim, Y.Y., et al., Anti-cancer effects of celecoxib in head and neck carcinoma.
Mol Cells, 2010. 29(2): p. 185-94.

62.

Feng, L. and Z. Wang, Chemopreventive effect of celecoxib in oral precancers
and cancers. Laryngoscope, 2006. 116(10): p. 1842-5.

63.

Wang, Z., C.F. Fuentes, and S.M. Shapshay, Antiangiogenic and chemopreventive
activities of celecoxib in oral carcinoma cell. Laryngoscope, 2002. 112(5): p.
839-43.

64.

Lang, S., et al., Impaired monocyte function in cancer patients: restoration with a
cyclooxygenase-2 inhibitor. FASEB J, 2003. 17(2): p. 286-8.

65.

Gillespie, M.B., et al., Head and neck cancer recurrence and mortality in
nonselective cyclooxygenase inhibitor users. Arch Otolaryngol Head Neck Surg,
2007. 133(1): p. 28-31.

66.

Shin, D.M., et al., Chemoprevention of head and neck cancer by simultaneous
blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling
pathways: preclinical and clinical studies. Clin Cancer Res, 2013. 19(5): p. 124456.

67.

Saba, N.F., et al., Chemoprevention of head and neck cancer with celecoxib and
erlotinib: results of a phase ib and pharmacokinetic study. Cancer Prev Res
(Phila), 2014. 7(3): p. 283-91.

68.

Wirth, L.J., et al., Phase I study of gefitinib plus celecoxib in recurrent or
metastatic squamous cell carcinoma of the head and neck. J Clin Oncol, 2005.
23(28): p. 6976-81.

69.

Bao, Y.S., et al., The regulation of CD4+ T cell immune responses toward Th2
cell development by prostaglandin E2. Int Immunopharmacol, 2011. 11(10): p.
1599-605.

70.

MacKenzie, K.F., et al., PGE(2) induces macrophage IL-10 production and a
regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J
Immunol, 2013. 190(2): p. 565-77.
114
List of References

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
71.

Stolina, M., et al., Specific inhibition of cyclooxygenase 2 restores antitumor
reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol, 2000.
164(1): p. 361-70.

72.

Woodford, D., et al., An Inflammatory Cytokine Milieu is Prominent in
Premalignant Oral Lesions, but Subsides when Lesions Progress to Squamous
Cell Carcinoma. J Clin Cell Immunol, 2014. 5(3).

73.

Juretic, M., et al., Salivary levels of TNF-alpha and IL-6 in patients with oral
premalignant and malignant lesions. Folia Biol (Praha), 2013. 59(2): p. 99-102.

74.

Rhodus, N.L., et al., The feasibility of monitoring NF-kappaB associated
cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant
transformation of oral lichen planus. Mol Carcinog, 2005. 44(2): p. 77-82.

75.

Younes, F., et al., Expression of TNF and the 55-kDa TNF receptor in epidermis,
oral mucosa, lichen planus and squamous cell carcinoma. Oral Dis, 1996. 2(1): p.
25-31.

76.

Xia, J., et al., Expressions of CXCL12/CXCR4 in oral premalignant and
malignant lesions. Mediators Inflamm, 2012. 2012: p. 516395.

77.

Kotrashetti, V.S., et al., Immunohistochemical expression of TLR4 and TLR9 in
various grades of oral epithelial dysplasia and squamous cell carcinoma, and
their roles in tumor progression: a pilot study. Biotech Histochem, 2013. 88(6): p.
311-22.

78.

Bondad-Palmario, G.G., Histological and immunochemical studies of oral
leukoplakia: phenotype and distribution of immunocompetent cells. J Philipp Dent
Assoc, 1995. 47(1): p. 3-18.

79.

Ohman, J., et al., Langerhans cells and T cells sense cell dysplasia in oral
leukoplakias and oral squamous cell carcinomas--evidence for
immunosurveillance. Scand J Immunol, 2012. 76(1): p. 39-48.

80.

Costa, N.L., et al., Distinct expression of perforin and granzyme B in lip and oral
cavity squamous cell carcinoma. J Oral Pathol Med, 2011. 40(5): p. 380-4.

81.

Dalrymple, N.A. and E.R. Mackow, Endothelial cells elicit immune-enhancing
responses to dengue virus infection. J Virol, 2012. 86(12): p. 6408-15.

82.

Mulligan, J.K. and M.R. Young, Tumors induce the formation of suppressor
endothelial cells in vivo. Cancer Immunol Immunother, 2010. 59(2): p. 267-77.
115

List of References

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
83.

Vielma, S.A., et al., Skewing of immune cell cytokine production by mediators
from adipocytes and endothelial cells. Adipocyte, 2014. 3(2): p. 126-31.

84.

Forastiere, A., et al., Head and neck cancer. N Engl J Med, 2001. 345(26): p.
1890-900.

85.

Schoop, R.A., M.H. Noteborn, and R.J. Baatenburg de Jong, A mouse model for
oral squamous cell carcinoma. J Mol Histol, 2009. 40(3): p. 177-81.

86.

Somers, K.D., M. Koenig, and G.L. Schechter, Growth of head and neck
squamous cell carcinoma in nude mice: potentiation of laryngeal carcinoma by
17 beta-estradiol. J Natl Cancer Inst, 1988. 80(9): p. 688-91.

87.

O'Malley, B.W., Jr., et al., A new immunocompetent murine model for oral
cancer. Arch Otolaryngol Head Neck Surg, 1997. 123(1): p. 20-4.

88.

Simon, C., et al., An orthotopic floor-of-mouth cancer model allows
quantification of tumor invasion. Laryngoscope, 1998. 108(11 Pt 1): p. 1686-91.

89.

Gimenez-Conti, I., The hamster cheek pouch carcinogenesis model. Acta Odontol
Latinoam, 1993. 7(1): p. 3-12.

90.

Shklar, G., Development of experimental oral carcinogenesis and its impact on
current oral cancer research. J Dent Res, 1999. 78(12): p. 1768-72.

91.

Zenklusen, J.C., et al., Transforming growth factor-beta 1 expression in Syrian
hamster cheek pouch carcinogenesis. Mol Carcinog, 1994. 9(1): p. 10-6.

92.

Hecht, S.S., Tobacco carcinogens, their biomarkers and tobacco-induced cancer.
Nat Rev Cancer, 2003. 3(10): p. 733-44.

93.

Phillips, D.H., Smoking-related DNA and protein adducts in human tissues.
Carcinogenesis, 2002. 23(12): p. 1979-2004.

94.

Yuan, B., et al., Harvey ras (H-ras) point mutations are induced by 4nitroquinoline-1-oxide in murine oral squamous epithelia, while squamous cell
carcinomas and loss of heterozygosity occur without additional exposure. Cancer
Res, 1994. 54(20): p. 5310-7.

95.

Hawkins, B.L., et al., 4NQO carcinogenesis: a mouse model of oral cavity
squamous cell carcinoma. Head Neck, 1994. 16(5): p. 424-32.

116

List of References

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
96.

Smith, L.P. and G.R. Thomas, Animal models for the study of squamous cell
carcinoma of the upper aerodigestive tract: a historical perspective with review
of their utility and limitations. Part A. Chemically-induced de novo cancer,
syngeneic animal models of HNSCC, animal models of transplanted xenogeneic
human tumors. Int J Cancer, 2006. 118(9): p. 2111-22.

97.

Kanojia, D. and M.M. Vaidya, 4-nitroquinoline-1-oxide induced experimental
oral carcinogenesis. Oral Oncol, 2006. 42(7): p. 655-67.

98.

Vitale-Cross, L., et al., Chemical carcinogenesis models for evaluating
molecular-targeted prevention and treatment of oral cancer. Cancer Prev Res
(Phila), 2009. 2(5): p. 419-22.

99.

Czerninski, R., et al., Targeting mammalian target of rapamycin by rapamycin
prevents tumor progression in an oral-specific chemical carcinogenesis model.
Cancer Prev Res (Phila), 2009. 2(1): p. 27-36.

100.

De Costa, A.M., et al., Characterization of the evolution of immune phenotype
during the development and progression of squamous cell carcinoma of the head
and neck. Cancer Immunol Immunother, 2012. 61(6): p. 927-39.

101.

Johnson, S.D., A.M. De Costa, and M.R. Young, Effect of the premalignant and
tumor microenvironment on immune cell cytokine production in head and neck
cancer. Cancers (Basel), 2014. 6(2): p. 756-70.

102.

Pries, R., et al., Secretion of tumor-promoting and immune suppressive cytokines
by cell lines of head and neck squamous cell carcinoma. In Vivo, 2006. 20(1): p.
45-8.

103.

Smith, C.W., et al., The host environment promotes the development of primary
and metastatic squamous cell carcinomas that constitutively express
proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC. Clin Exp
Metastasis, 1998. 16(7): p. 655-64.

104.

Mann, E.A., et al., Cytokine expression by head and neck squamous cell
carcinomas. Am J Surg, 1992. 164(6): p. 567-73.

105.

Whiteside, T.L., Immunobiology of head and neck cancer. Cancer Metastasis Rev,
2005. 24(1): p. 95-105.

106.

Reichert, T.E., et al., Mechanisms responsible for signaling and functional
defects. J Immunother, 1998. 21(4): p. 295-306.

117

List of References

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
107.

Battersby, S., et al., Expression and localization of endothelial monocyteactivating polypeptide II in the human endometrium across the menstrual cycle:
regulation of expression by prostaglandin E(2). J Clin Endocrinol Metab, 2002.
87(8): p. 3928-35.

108.

Hashimoto, K., et al., Cyclooxygenase inhibition augments allergic inflammation
through CD4-dependent, STAT6-independent mechanisms. J Immunol, 2005.
174(1): p. 525-32.

109.

De Costa, A.M., et al., Administration of a vaccine composed of dendritic cells
pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced
premalignant oral lesions stimulates a protective immune response. Int
Immunopharmacol, 2012. 13(3): p. 322-30.

110.

Hubbard, L.L., et al., A role for IL-1 receptor-associated kinase-M in
prostaglandin E2-induced immunosuppression post-bone marrow
transplantation. J Immunol, 2010. 184(11): p. 6299-308.

111.

Stables, M.J., et al., Priming innate immune responses to infection by
cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria.
Blood, 2010. 116(16): p. 2950-9.

112.

Olesch, C., et al., MPGES-1-derived PGE2 suppresses CD80 expression on
tumor-associated phagocytes to inhibit anti-tumor immune responses in breast
cancer. Oncotarget, 2015. 6(12): p. 10284-96.

113.

Dunn, G.P., L.J. Old, and R.D. Schreiber, The three Es of cancer immunoediting.
Annu Rev Immunol, 2004. 22: p. 329-60.

114.

Xiao, M., et al., IFNgamma promotes papilloma development by up-regulating
Th17-associated inflammation. Cancer Res, 2009. 69(5): p. 2010-7.

115.

Roberts, S.J., et al., Characterizing tumor-promoting T cells in chemically
induced cutaneous carcinogenesis. Proc Natl Acad Sci U S A, 2007. 104(16): p.
6770-5.

116.

Kesselring, R., et al., Human Th17 cells can be induced through head and neck
cancer and have a functional impact on HNSCC development. Br J Cancer, 2010.
103(8): p. 1245-54.

117.

McAllister, F., et al., Oncogenic Kras activates a hematopoietic-to-epithelial IL17 signaling axis in preinvasive pancreatic neoplasia. Cancer Cell, 2014. 25(5):
p. 621-37.
118

List of References

Immune Changes Associated with Progression of Premalignant Lesions to HNSCC
118.

Wang, L., et al., IL-17 enhances tumor development in carcinogen-induced skin
cancer. Cancer Res, 2010. 70(24): p. 10112-20.

119.

Gnerlich, J.L., et al., Induction of Th17 cells in the tumor microenvironment
improves survival in a murine model of pancreatic cancer. J Immunol, 2010.
185(7): p. 4063-71.

120.

Qian, X., et al., Increased Th17 cells in the tumor microenvironment is mediated
by IL-23 via tumor-secreted prostaglandin E2. J Immunol, 2013. 190(11): p.
5894-902.

121.

Chinen, T., et al., Prostaglandin E2 and SOCS1 have a role in intestinal immune
tolerance. Nat Commun, 2011. 2: p. 190.

119

List of References

